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ABSTRACT
     Background. Diabetic nephropathy (DN) is a major microvascular complication of
diabetes and a common cause of end-stage renal disease (ESRD) worldwide. DN first
manifests as a small amount of albumin in urine (microalbuminuria) that develops into overt
albuminuria as nephropathy progresses. The pathological features of DN include glomerular
and tubular basement membrane thickening, mesangial extracellular matrix expansion, and
glomerular visceral epithelial cell (podocyte) loss and podocyte foot process effacement.
Podocytes are part of the glomerular filtration barrier and play an important role in the
development of DN, as hyperglycemia may activate pathways that lead to their injury and
loss. Interestingly, insulin signaling in podocytes is essential for maintaining normal kidney
function as deficiency in insulin receptor (IR) signaling in podocytes can induce a disease
state reminiscent of DN. Insulin resistance is also a risk factor for DN, and has been reported
to be associated with microalbuminuria in both patients with Type 1 and Type 2 diabetes. At
the cellular level, the mechanisms leading to the development of insulin resistance include
mutations in the IR itself, as well as impairments in the phosphoinositide 3-kinase
(PI3K)/AKT signaling pathway or glucose transporter trafficking that regulate the uptake of
glucose into cells. In podocytes, insulin rapidly induces remodelling of the actin cytoskeleton
and leads to glucose uptake via glucose transporters 1 (GLUT1) and glucose transporters 4
(GLUT4). This process requires nephrin, which facilitates GLUT4 storage vesicle (GSV)
fusion with the plasma membrane. However, the precise mechanisms regulating GSV
trafficking and glucose uptake into podocytes are largely uncharacterized.
Results. To characterize the early pathophysiological mechanisms leading to podocyte
injury in DN, we performed quantitative proteomic profiling of glomeruli isolated from
control rats as well as those with streptozotocin-induced diabetes. Ezrin was found to be
downregulated in diabetic glomeruli. In cultured podocytes, depletion of ezrin increased
glucose uptake apparently by increasing translocation of glucose transporter GLUT1 to the
plasma membrane. Loss of ezrin also induced actin remodelling under basal conditions, but
reduced insulin-stimulated actin reorganization. Ezrin-dependent actin remodelling involved
cofilin-1. Phosphorylated, inactive cofilin-1 was upregulated in diabetic glomeruli,
suggesting altered actin dynamics. Furthermore, reduced expression of ezrin was found in the
podocytes of human patients with diabetes.
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     Adaptor protein CD2-associated protein (CD2AP) interacts with nephrin and is essential
for glomerular ultrafiltration. We found that the filament-forming GTPase septin 7 is also part
of the CD2AP-nephrin protein complex. Septin 7 negatively regulates GSV trafficking by
forming a physical barrier between the vesicles and the plasma membrane. To further
characterize the function of septin 7 in regulating GSV trafficking, we searched for
interaction partners of septin 7 and identified nonmuscle myosin heavy chain IIA (NMHC-
IIA). Nonmuscle myosin IIA (NM-IIA) consists of heavy chains and essential and regulatory
light chains. We observed that depletion of NMHC-IIA decreases insulin-stimulated glucose
uptake into podocytes. Thus, septin 7 and NMHC-IIA play opposite roles in glucose
transport. Septin 7 and phosphorylated myosin regulatory light chain (pp-RLC) compete for
binding to SNAP23 (synaptosome-associated protein, 23 kDa), a plasma membrane SNARE
(N-ethylmaleimide–sensitive fusion protein attachment protein receptor) protein involved in
GSV exocytosis. Furthermore, insulin regulates the association of septin 7 and pp-RLC with
SNAP23. Depletion of NMHC-IIA inhibits the association of VAMP2 (vesicle-associated
membrane protein 2) with SNAP23 indicating that SNARE complex formation is reduced in
the absence of NMHC-IIA. pp-RLC is upregulated in diabetic glomeruli and cultured human
podocytes exposed to macroalbuminuric sera from patients with Type 1 diabetes. The data
indicate that pp-RLC facilitates glucose uptake into podocytes. Activation of NM-IIA by
phosphorylation of its RLC in glomeruli in diabetes suggests that NM-IIA may play a role in
the development of DN.
     Conclusions. Our findings indicate that ezrin, septin 7 and NMHC-IIA regulate glucose
uptake into podocytes and may play a role in the development of renal complications in
diabetes by regulating glucose transport and organization of the actin cytoskeleton in
podocytes.
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1 INTRODUCTION
     Diabetes mellitus is a rapidly-growing global problem with social, health, and economic
consequences. It is a chronic disease that occurs when the pancreas is no longer able to
produce insulin (Type 1 diabetes mellitus, T1DM; insulin-dependent diabetes mellitus,
IDDM), or when the cells fail to use insulin properly (Type 2 diabetes mellitus, T2DM; non
insulin-dependent diabetes mellitus, NIDDM). Approximately 382 million people suffer from
diabetes and the number is estimated to increase up to 592 million by 2035 (International
Diabetes Federation, 2013). All forms of diabetes increase the risk of long-term micro- and
macrovascular complications. The microvascular complications refer to diabetic nephropathy,
retinopathy and neuropathy, and the macrovascular complications include cardiovascular
disease, stroke and peripheral vascular disease. Diabetes is now the most common cause of
ESRD (Zimmet et al., 2001).
     Diabetic nephropathy (DN) affects around 40% of patients with diabetes, and the
proportion of patients with ESRD caused by diabetes has progressively increased during the
last few decades. DN is associated with increased risk of cardiovascular disease and mortality
(Nathan et al., 2005; Groop et al., 2009) and with metabolic syndrome (Thorn et al., 2005).
Four major histologic pathological features are observed in DN: (I) mesangial expansion, (II)
glomerular basement membrane (GBM) thickening, (III) podocyte foot process effacement
and podocyte apoptosis, and (IV) hyalinosis of afferent and efferent arterioles.
     Hemodynamic (glomerular hypertension) and metabolic (hyperglycemia) factors
contribute to the development and progression of diabetic kidney disease (DKD).
Hemodynamic pathways include elevations of systemic and intraglomerular pressure and
activation of various vasoactive hormone pathways, including the renin-angiotensin
aldosterone system (RAAS), endothelin, and urotensin. Hyperglycemia results in
accumulation of advanced glycated end-products (AGEs) and reactive oxygen species (ROS),
and activation of the polyol and hexosamine pathways. This promotes activation of
intracellular secondary messengers including protein kinases, transcription factors and growth
factors  which  lead  to  modulation  of  the  immune  system  and  activation  of  the  enzymes
involved in glucose metabolism. Collectively, these factors increase albumin excretion rate
(AER), extracellular matrix accumulation, cell hypertrophy and apoptosis (reviewed in
Brownlee et al., 2001; reviewed in Soldatos and Cooper, 2008). Excess glucose may
therefore activate several pathways that lead to podocyte injury (Lewko and Stepinski, 2009).
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     Insulin resistance may play a role in the development of kidney injury, as both clinical and
experimental data suggest that insulin sensitizers have a renoprotective role in diabetes
patients (Miyazaki et al., 2007), as well as in animal models (Zhang et al., 2008). Insulin
resistance is associated with an increased risk of chronic kidney disease, microalbuminuria
and overt proteinuria (Kurella et al., 2005; Chen et al., 2008; Ryu et al., 2009; Thomas et al.,
2011). Interestingly, podocytes are uniquely insulin sensitive cells in the glomerulus of the
kidney (Coward et al., 2005) and podocyte insulin resistance has been first demonstrated in
early diabetes in T2DM db/db mice (Tejada et al., 2008). Podocyte-specific IR knockout
mice develop albuminuria and histological features of DN even in the setting of
normoglycemia (Welsh et al., 2010). Interestingly, the podocyte protein nephrin is crucial for
the insulin sensitivity of podocytes (Coward et al., 2007) and its expression was shown to be
reduced in early DN (Patari et al., 2003; Doublier et al., 2003; Jim et al., 2012). The inability
of podocytes to respond to insulin may also result from upregulation of C-jun N-terminal
kinase (JNK), a negative regulator of insulin signaling, as observed in glomeruli of db/db
mice (Ijaz et al., 2009). In cultured human podocytes, saturated fatty acids induce insulin
resistance in vitro (Lennon  et  al.,  2009).  Also,  the  protein  tyrosine  phosphatase  SHP-1
(Drapeau et al., 2013), lipid phosphatase SHIP2 (Hyvönen et al., 2010) and Synip (Yamada et
al., 2014) regulate insulin sensitivity of podocytes. In addition, hyperinsulinemia also appears
to induce kidney dysfunction by promoting glomerular hyperfiltration and increased vascular
permeability (reviewed in De Cosmo et al., 2013).
     It is clear that podocytes have a functional system for glucose uptake (Lewko et al., 2005).
Glucose uptake is initiated by the activation of the IR by insulin, which leads to a cascade of
signaling events that coordinate translocation of GSV to the plasma membrane. The PI3K and
the cGMP-dependent protein kinase G signaling pathways are implicated in the regulation of
GSV trafficking in podocytes. Glucose uptake into podocytes is achieved through the
facilitative glucose transporters GLUT1 and GLUT4 and depends on the slit diaphragm (SD)
protein nephrin (Coward et al., 2007). GLUT2 and GLUT8 have also been observed in
podocytes (Lewko et al., 2005; Schiffer et al., 2005), but their role in glucose uptake in these
cells remains uncharacterized. GSV translocation to the plasma membrane occurs in multiple
stages including approaching, tethering, docking and fusion. Actin and microtubule-based
cytoskeleton provide a route for the vesicles to approach the plasma membrane. The exocyst
complex  proteins  help  tether  the  GSVs  to  the  plasma  membrane,  and  formation  of  the
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SNARE  complex  between  vesicle  SNARE  (v-SNARE)  and  target  SNAREs  (t-SNARE)
mediates fusion of the GSVs with the plasma membrane (reviewed in Stöckli et al., 2011).
     The studies in this thesis were initiated by characterization of the early molecular changes
associated with the development of diabetic kidney injury by a comparative proteomics
approach. We found that ezrin, an actin-binding protein, increases the dynamic reorganization
of actin in podocytes and regulates glucose uptake via GLUT1. Futhermore, cofilin-1 was
found to be involved in ezrin-mediated cortical actin remodelling. We also identified septin 7
as a novel interaction partner of CD2AP and nephrin, and characterized the function of septin
7 in podocytes. Our data indicate that septin 7 hinders GSV trafficking by forming a physical
barrier between the vesicles and the plasma membrane and negatively regulates glucose
uptake into podocytes. Septin 7 also competes with active nonmuscle myosin IIA for binding
to the SNARE complex to regulate glucose uptake into podocytes. These results suggest that
the regulators of glucose transporter trafficking and actin reorganization may associate with
the development of diabetic kidney complications and provide suitable targets to enhance
insulin sensitivity of podocytes.
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2 REVIEW OF THE LITERATURE
2.1  Overview of kidney structure and function
     The kidneys perform several major functions in the body. They play a vital role in normal
physiology by maintaining fluid and electrolyte balance, acid-base balance, and glucose
balance via glucose reabsorption and/or gluconeogenesis. They also excrete metabolic waste
products and foreign chemicals, and secrete hormones that regulate blood pressure and red
blood cell formation.
The basic structural and functional unit of the kidney is the nephron, which spans the
kidney cortex and medulla. Each human kidney has about 1 million nephrons. A nephron
consists of a glomerulus and a tubulus. A glomerulus consists of a capillary tuft located inside
the Bowman’s capsule (Figure 1B). The glomeruli localize in the kidney cortex, and they are
responsible for plasma filtration. The distal part of the nephron is the tubular system that
passes from the cortex deep into the kidney medulla (Figure 1A) and which is further divided
into  the  proximal  and  distal  tubule  and  the  Loop of  Henle.  After  passing  through the  renal
tubule, the filtrate continues to the single collecting duct (Figure 1B).
     Every day, about 180 liters of primary urine is normally formed by the kidney glomeruli.
The tubular system allows the reabsorption of water and electrolytes, such that the final daily
excretion is normally only ~1–1.5 liters.
Figure 1. Schematic illustration of kidney (A) and nephron (B) anatomy. Modified from
Marieb, 2001.
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2.2 Glomerular filtration barrier
     The size-, charge- and shape-selective ultrafiltration of plasma occurs in glomeruli (Figure
2A). Primary urine is filtrated from the plasma through the glomerular filtration barrier
(GFB) to the Bowman’s space and then passes to the tubular system. Water and small
molecules pass the barrier, whereas molecules the size of albumin (~67 kDa) and larger are
retained in the blood. The GFB consists of three distinct layers: the fenestrated endothelium,
the glomerular basement membrane (GBM), and the podocytes with their slit diaphragms
(SD) (Figure 2B).
Figure 2. Schematic structure of the glomerulus (A) and the glomerular filtration
barrier (B). SD:  slit  slit  diaphragm.  Modified  from  Komorniczak,  2009  (A)  and  Suh  and
Miner, 2013 (B).
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2.2.1 Endothelium
     The glomerular endothelium is the first part of the GFB that lines the interior surface of
the glomerular capillaries. The presence of numerous trans-cellular holes (fenestrations) of
70–100 nm in diameter (in humans) provides the first structural barrier to albumin (reviewed
in Haraldsson et al., 2008). The luminal side of the endothelial cells and the fenestrations are
covered by an endothelial cell coat and a glycocalyx composed of proteoglycans,
glycosaminoglycans, glycoproteins and glycolipids. Due to its negative charge, glycocalyx
contributes to the charge-selective properties of the GFB (Jeansson and Haraldsson, 2006).
The endothelium is involved also in the formation of the GBM by synthesizing laminin (St
John and Abrahamson, 2001) and type IV collagen (Abrahamson et al., 2009). The
endothelial cells communicate with the podocytes and the mesangial cells through a variety
of signaling pathways in order to prevent proteinuria (Davis et al., 2007; Daehn et al., 2014).
2.2.2 Glomerular basement membrane
     The GBM is an amorphous, 300- to 350-nm-thick extracellular structure that is surrounded
and maintained by endothelial cells and podocytes. The GBM can be separated into three
layers: lamina rara externa (outer, underneath the foot processes), lamina densa (central) and
lamina rara interna (inner, subendothelial). The main components of the GBM include type
IV collagen, laminin, nidogen (entactin) and heparan sulfate proteoglycans (HSPGs) which
provide an anionic charge to the GBM and have been considered to contribute to the charge-
selective filtration barrier (reviewed by Haraldsson et al., 2008).
2.2.3 Podocytes
     Podocytes are polarized, highly specialized and terminally differentiated cells that
surround the glomerular capillaries and form a key part of the glomerular filtration barrier.
With respect to their cytoarchitecture, podocytes consist of three different segments. The cell
body gives rise to major processes that branch into a network of interdigitating cellular
extensions called foot processes. The foot processes of neighboring podocytes interact
between the basal and apical sides of the podocytes with specialized 40-nm-wide cell-to-cell
junctions called slit diaphragms (SD) (reviewed in Pavenstädt et al., 2003). The SD is highly
permeable to water and small molecules, but not to larger proteins, like albumin. Podocyte
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damage leads to retraction of the foot processes. Thus, during proteinuric diseases like
diabetes mellitus, the foot processes lose their fine structure and collapse.
2.2.4 Mesangium
     The mesangium consists of mesangial cells and their surrounding matrix and is located
between the capillary loops of the glomerular tuft (reviewed by Haraldsson et al., 2008). The
major role of the mesangium is to provide structural support for the glomerular capillaries.
Mesangial cells resemble smooth muscle cells by having contractile properties; therefore they
participate in the regulation of glomerular filtration (Becker, 1972; Ausiello et al., 1980).
They also control the composition and turnover of the mesangial  matrix (reviewed in Veis,
1993) and contribute to the removal of glomerular debris due to their phagocytic activity
(Mauer et al., 1972; Elema et al., 1976).
2.3 Podocyte biology
     Podocytes are polarized epithelial cells with apical, basal and junctional cell membrane
domains (reviewed in Kerjaschki, 2001). The apical domain is facing the Bowman's space,
and is characterized by the expression of podocalyxin. The basal domain is required to anchor
the podocyte to the underlying GBM. The junctional domain contains a nephrin-based
multimeric protein complex, which forms  a  SD,  bridging  the  adjacent  foot  processes.  The
submembranous regions of all compartments are connected to the podocyte actin
cytoskeleton (reviewed in Pavenstädt et al., 2003).
2.3.1 Slit diaphragm
     The SD represents the only cell-cell contact between podocytes. The major component of
the SD is nephrin (Ruotsalainen et al., 1999). Nephrin is a transmembrane protein of the
immunoglobulin (Ig) superfamily and, together with the Neph-protein family (Neph 1-3),
forms a framework of the SD (Ruotsalainen et  al.,  1999; Barletta et  al.,  2003; Gerke et  al.,
2003; Wartiovaara et al., 2004; Gerke et al., 2005). Based on its components, the SD is
considered as a special cell adhesion structure with characteristics of both adherens and tight
junctions (Schnabel et al., 1990; Reiser et al., 2000). Adherens junctions mediate cell to cell
contact. The adherens junction proteins present in SD include cadherin family protein P-
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cadherin (Reiser et al., 2000) and vascular endothelial (VE)-cadherin (Cohen et al., 2006), as
well as catenins (Reiser et al., 2000; Lehtonen et al., 2004) and FAT1 (Inoue et al., 2001).
Tight junctions act as cellular barriers for the transport of water, ions and proteins (Anderson,
2001), and function in maintaining cell polarity (Shin et al., 2006). The tight junction-
associated proteins detected in the SD include Zonula occludens-1 (ZO-1) (Schnabel et al.,
1990), membrane associated guanylate kinase inverted-1 (MAGI-1) (Hirabayashi et al.,
2005), MAGI-2 (Lehtonen et al., 2005), calmodulin associated serin/threonine kinase
(CASK) (Lehtonen et al., 2004), and junction adhesion molecule-1 (JAM-1) (Fukasawa et al.,
2009). In addition, several other molecules, including cytoplasmic CD2AP (Shih et al., 1999)
and podocin (Schwarz et al., 2001) have been shown to be connected to the SD.
     The SD is a multifunctional protein complex which sends signals regulating cell polarity,
cell survival and cytoskeleton organization. Phosphorylation of nephrin and Neph1 initiates
signaling pathways in podocytes (reviewed in Benzing, 2004), and podocin contributes to
intracellular signal transduction via interaction with nephrin (Boute et al., 2000; Huber et al.,
2003; Li et al., 2004). CD2AP, together with nephrin, activates PI3K and stimulates
serine/threonine kinase AKT-dependent signaling (Li et al., 2000; Huber et al., 2003).
CD2AP and ZO-1 also appear to connect the SD to the actin cytoskeleton (Fanning et al.,
2002; Lehtonen et al., 2002; Huber et al., 2003).
2.3.2 Basal domain of podocytes
     The basal domain of podocyte foot processes is attached to the GBM via cell-matrix
contacts. Two major podocyte adhesion receptors, α3β1-integrin complex and the
dystroglycan complex, bind to GBM ligands such as collagen IV, laminin, and perlecan. Both
integrins and dystroglycans are coupled to the actin cytoskeleton via adaptor molecules.
Therefore, mechanical force can be transmitted from the GBM to the cytoskeleton of the foot
processes and further to the podocyte cell body. The foot procesess are also involved in
GBM turnover. They secrete matrix-modifying enzymes and participate in the synthesis and
assembly of the GBM molecules (reviewed in Miner, 1999).
     Studies showed reduced dystroglycan level in minimal change disease (Regele et al.,
2000). During podocyte injury, altered interactions of dystroglycan with the GBM leads to
podocyte effacement (Kojima et al., 2004), characterized by flattening of foot processes and
reduction  of  the  frequency  of  SD. β1 integrin–null mice die at birth and show effaced
podocytes (Kreidberg et al., 1996).
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2.3.3 Apical domain of podocytes
     The apical membrane domain of podocytes is located on the luminal side, facing the
urinary space. It has a negatively charged surface coat, consisting mainly of the anionic
sialoprotein podocalyxin (Kerjaschki et al., 1984). This negative charge limits the passage of
negatively charged proteins into the urinary space, prevents parietal cell adherence to
podocytes, and keeps adjacent podocytes separated (Takeda et al., 2000). Podocalyxin is
connected to the cortical actin cytoskeleton via the interaction with Na+/H+ exchange
regulatory factor 2 (NHERF2) and activated ezrin (Takeda et al., 2001).
     Studies have shown that the podocalyxin-rich apical membrane of podocytes is shed into
the urine of patients with nephric syndrome and nephritis, indicating podocyte injury (Hara et
al., 2005). Furthermore, disruption of podocalyxin or reduction of its negative charge results
in dissociation of podocalyxin from the actin cytoskeleton, leading to foot process effacement
(Takeda et al., 2001) and rearrangement of the cell-cell contacts between neighboring
podocytes (Kurihara et al., 1992).
2.3.4 Podocyte cytoskeleton
     The highly dynamic foot processes contain an actin-based cytoskeleton. The podocyte
cytoskeleton is critical for structural integrity of the foot processes, coupling of the slit
membrane complex with podocyte-GBM contacts, and maintaining of the mechanical
strength and flexibility of the podocytes. The cytoskeleton of the major processes maintains
contact with the metabolic machinery of the podocyte cell body and allows vesicular
transport along the foot process.
2.3.4.1 Actin cytoskeleton assembly and reorganization
     The precise organization and regulation of the actin cytoskeleton in podocytes are
essential for the maintenance of the normal structure and function of these cells. Actin
reorganization is a highly dynamic process, governed by continuous assembly and
disassembly of the actin filaments. Signaling from all three podocyte domains is required for
the regulation of the actin reorganization. Actin filaments can be organized in packed arrays
or loosely associated in networks. The level of actin packing is defined by the actin cross-
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linking molecule, α-actinin, and the associated motor proteins (like myosins), allowing
contraction of the actin apparatus (Gordon et al., 2000).
     Nck and its associated actin cytoskeleton regulatory proteins, including Wiskott-Aldrich
syndrome protein (N-WASp) and actin-related protein (Arp2/3), are recruited to
phosphorylated nephrin when rapid actin polymerization and cytoskeletal reorganization are
required  (Verma  et  al.,  2006).  The  formation  of  new  actin  filaments  is  promoted  by  the
Arp2/3 complex, which nucleates new filaments from the sides of preexisting filaments and
thus induces the formation of a branched filament network (Mullins et al., 1998; Svitkina and
Borisy, 1999).
     The  assembly  of  actin  filaments  is  regulated  by  the  small  GTPases:  RhoA,  Rac1  and
Cdc42 (Heasman and Ridley, 2008).  RhoA directly initiates stress fiber assembly through its
effectors, including Rho-associated protein kinase (ROCK) (Leung et al., 1996). ROCK in
turn promotes stress fiber formation by inhibiting actin filament depolymerization through
inactivation of actin depolymerizing factor/cofilins via LIM kinase and by inducing
contractility through phosphorylation of myosin light chains. Phosphorylation of cofilin-1 on
serine 3 leads to its inactivation resulting in reduced binding to actin and depolymerizing
activity (Moriyama et al., 1996; Heyworth et al., 1997).
2.3.4.2 Components of the podocyte cytoskeleton
     Podocyte function and architecture depend on the precise organization of three sets of
elements: microfilaments (7-9 nm in diameter), intermediate filaments (10 nm in diameter)
and microtubules (24 nm in diameter). The podocyte cell body and major processes contain
microtubules and intermediate filaments like tubulin and vimentin (Drenckhahn and Franke,
1988; Cortes et al., 2000), whereas the foot processes contain dense actin filaments which are
anchored to the GBM, the SD and the apical domain (Figure 3). There are two actin
cytoskeletal networks in the foot processes: dense actin bundles above the level of the SD
running parallel to the longitudinal axis, and a cortical actin network just below the plasma
membrane of the foot processes (revieved in Pavenstädt et al., 2003) (Figure 3).
     The cytoskeleton maintains the shape of podocytes and enables continuous adapting. The
cytoskeleton supports the glomerular capillary wall and opposes the high hydrostatic pressure
necessary for glomerular filtration. To fulfill these functions, the actin network is modified by
an assembly of linker and adaptor proteins.
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Figure 3. Molecular components of the podocyte foot processes actin cytoskeleton.
CD2AP: CD2-associate protein; DG: dystroglycan; GBM: glomerular basement membrane;
NHERF2: Na+/H+ exchange regulatory factor 2; P-Cad: P-cadherin. Modified from Mundel
and Shankland, 2002.
2.3.4.3 Podocyte proteins that regulate actin
     The assembly, maintenance, and disassembly of the actin cytoskeleton are mediated by a
variety of actin-associated proteins with divergent molecular interactions and functional
properties (reviewed in Zigmond, 1996) (Figure 3). Therefore, proteins regulating or
stabilizing the actin cytoskeleton are of critical importance for sustained function of
glomerular filtration (Shirato et al., 1996; Takeda et al., 2001; Smoyer and Randstom, 2002).
Mutations in many of these proteins lead to kidney dysfunction.
     α-actinin-4. α-actinin-4, an actin-binding protein which is localized to podocyte foot
processes (Kaplan et al., 2000), has an important role in cross-linking of actin filaments into
contractile bundles and in helping to form the anchoring complex for the ends of actin stress
fibers. Mutations of ACTN4, encoding α-actinin, were found to cause a late-onset autosomal-
dominant  focal  segmental  glomerulosclerosis  (FSGS)  in  humans  (Kaplan  et  al.,  2000)  and
podocyte-specific expression of mutant α-actinin 4 in mice leads to FSGS (Michaud et al.,
2003). Actin filaments cross-linked by the mutant α-actinin-4 exhibit profound changes in
structural and biomechanical properties (Weins et al., 2007), e.g. increased F-actin bundling
and altered flexibility (Ward et al., 2008). Induction of proteinuria with puromycin in rats
results in progressive podocyte damage due to an increase in α-actinin 4 expression (Shirato
et al., 1996; Smoyer et al., 1997).
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     Ezrin. Ezrin, a member of of ezrin/radixin/moesin (ERM) family of actin-binding proteins
(Arpin et al., 1994; Vaheri et al., 1997; Tsukita and Yonemura, 1999), is an important
regulator of actin dynamics and links membrane proteins to the underlying actin cytoskeleton
(Arpin et al., 1994; Vaheri et al., 1997). In glomeruli, ezrin is expressed in podocytes (Hugo
et al., 1998), and together with NHERF2, connects the cell surface sialoprotein podocalyxin
to actin (Takeda et al., 2001).
Cofilin-1. Cofilin-1 is an actin modulating protein that severs and depolymerizes F-actin
and enhances dynamics of actin filaments (Nishida et al., 1984; Yonezawa et al., 1985;
Theriot, 1997). Cofilin-1 plays a key role in regulating the actin cytoskeleton in podocytes
(Garg et al., 2010; Ashworth et al., 2010). Knockdown or mutation of cofilin-1 disturbs the
filtration barrier in zebrafish (Ashworth et al., 2010). Mice with podocyte-specific cofilin-1
deletion develop proteinuria by the age of 3 months (Garg et al., 2010).
     CD2AP. CD2AP is cytoplasmic multifunctional adaptor protein that contains three SH3
(Src homology 3) domains at its N-terminus, proline-rich domains and a coiled-coil domain
at the C-terminus. CD2AP localizes at the intracellular insertion site of the SD (Shih et  al.,
2001) and functions as a scaffolding protein connecting the actin cytoskeleton to plasma
membrane proteins, such as nephrin and podocin (Shih et al., 2001). CD2AP interacts
directly with actin (Lehtonen et al., 2002) and the actin-binding proteins CapZ (Hutchings et
al., 2003) and cortactin (Lynch et al., 2003). Thus, CD2AP has a role in the regulation of the
actin cytoskeleton. Mice lacking CD2AP develop severe nephrotic syndrome and foot
process effacement at the age of 2-3 weeks and die of renal failure at age of 6-7 weeks (Shih
et al., 1999). Mutations in CD2AP have also been reported in human patients with FSGS
(Kim et al., 2003; Gigante et al., 2009). Moreover, CD2AP plays an important role in
albumin overload-induced podocyte injury via disruption of the cytoskeleton (He et al.,
2011).
     Nephrin. Nephrin, a major structural protein of the SD, regulates actin dynamics in many
ways.  It  interacts  with  the  adaptor  protein  CD2AP and with  IQGAP,  an  effector  protein  of
small GTPases Rac1 and Cdc42 (Shih et al., 1999; Liu et al., 2004). Nephrin is known to be
in  complex  with  the  Nck  adaptor  protein,  which  controls  actin  polymerization  and  is  a
potential regulator of actin cytoskeleton dynamics by recruiting the Arp2/3 complex (Jones et
al., 2006). Furthermore, nephrin regulates the PI3K/protein kinase B pathway that is
important for actin reorganization (Zhu et al., 2008). The human nephrin gene, NPHS1, is
mutated in the congenital nephrotic syndrome of the Finnish type (CNF) (Kestilä et al.,
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1998). In mice, inactivation of the nephrin gene results in a phenotype that resembles the
findings in CNF patients (Putaala et al., 2001; Rantanen et al., 2002).
     Nonmuscle myosin II. Nonmuscle myosin II (NM-II) is an actin-based motor protein that
plays an essential role in actin cytoskeleton organization and cellular motility. It is composed
of  two  heavy  chains  and  two  pairs  of  light  chains.  Nonmuscle  myosin  heavy  chain  IIA
(NMHC-IIA) is a component of the actin cytoskeleton of podocyte foot processes (Endlich et
al., 2001). Mutations in the MYH9 gene, encoding NMHC-IIA, cause four autosomal
dominant syndromes with variable degrees of nephropathy (Epstein et al., 1972; Peterson et
al.,  1985;  Greinacher  et  al.,  1990).  NMHC-IIA  has  also  been  associated  with  FSGS  and
ESRD (Kopp et al., 2008). Mouse models with Myh9-related diseases manifest similar
phenotypes as observed in humans (Zhang et al., 2012), and podocyte-specific deletion of
Myh9 predisposes mice to glomerulopathy depending on the genetic background and the
model of experimental injury (Johnstone et al., 2011; Zhang et al., 2012, Johnstone et al.,
2013). Furthermore, knockdown of NMHC-IIA in zebrafish indicates that NMHC-IIA is
essential for the formation and function of the glomerulus (Müller et al., 2011).
2.4  Diabetic nephropathy
     DN is a microvascular complication of diabetic mellitus that affects around 40% of
patients with diabetes. DN is the most common cause of renal replacement therapy
worldwide (Zimmet et al., 2001).
2.4.1 Definition and clinical features of diabetic nephropathy
     DN  is  categorized  based  on  the  albumin  excretion  rate  (AER).  The  first  sign  of  DN  is
microalbuminuria (incipient nephropathy), defined as AER 20-200 µg/min or 30-300 mg/24
h. Macroalbuminuria (AER >200 µg/min or >300 mg/24 h) or proteinuria (AER >500 mg/24
h), considered as overt nephropathy, occur over a period of years and subsequently lead to a
decrease in estimated glomerular filtration rate (eGFR <60 ml/min/1.73 m2) (Reutens and
Atkins, 2011).
     Microalbuminuria appears 5–15 years after the patient is diagnosed with diabetes mellitus.
The AER values are predictors of DN (Viberti et al., 1982; Mogensen and Christensen,
1984), as AER increases with time. Microalbuminuria has been considered as a risk factor for
macroalbuminuria (Caramori et al., 2000). Studies in 1980s showed that around 80% of
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T1DM patients with microalbuminuria progress to overt proteinuria within 6-14 years
(Viberti et al., 1982; Parving et al., 1982). However, this is not common in all patients. In
some of the patients microalbuminuria may regress to normoalbuminuria (Perkins et al.,
2003). Studies have shown that only 30-40% of those patients with microalbuminuria
progress to macroalbuminuria within 10 years (Caramori et al., 2000) mostly due to the
intensive glycemic and blood pressure control. The same is true for patients with T2DM
(Adler et al., 2003).
     Once microalbuminuria/macroalbuminuria presents, renal function progressively declines
and ESRD develops. In early diabetes, increased GFR is commonly present (Wiseman et al.,
1985; Caramori et al., 1999). As DN develops, GFR gradually decreases (Viberti et al., 1983;
Skupien et al., 2012). Studies have reported that a subset of normoalbuminuric T1DM
patients do not progress to macroalbuminuria despite reduced GFR and advanced renal
lesions (Caramori et al., 2003; Molitch et al., 2010). This finding has been confirmed also for
patients with T2DM (Kramer et al., 2003; MacIsaac et al., 2004).
2.4.2 Pathological features of diabetic nephropathy
     DN is characterized by the presence of specific and pathological renal changes. The
changes start early in the course of diabetes and progress as the disease develops. The
pathology of the renal lesions is similar in T1DM and T2DM (Taft et al., 1994), although it
has been suggested that there is more heterogeneity in T2DM (Chihara et al., 1986). In DN,
the morphology of all four compartments in the kidney, glomeruli, tubuli, interstitium and
vessels are affected.
2.4.2.1 Glomerular changes
     The characteristic histological change in glomeruli in DN is mesangial matrix
accumulation (Kimmelstiel and Wilson, 1936) due to increased production or reduced
degradation of extracellular matrix (ECM) proteins (Schnaper et al., 1996). Mesangial
expansion can be nodular (so-called Kimmelstein-Wilson nodules) and associates with
reduced filtration surface area in glomeruli and, consequently, with reduced GFR and
progressing albumin excretion (Mauer et al., 1984; Fioretto et al., 1995). The main
ultrastructural and earliest detectable change in diabetic kidneys is the thickening of the GBM
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due to increased accumulation of the extracellular matrix. GBM thickening may be detected
as early as 1.5-2.5 years after the onset of T1DM (Osterby, 1973), even in normoalbuminuric
patients (Perrin et al., 2006). Evidence for podocyte injury, including foot process widening
and podocyte loss due to apoptosis has also been reported (Susztak et al., 2006) (Figure 4).
Figure 4. Characteristic glomerular filtration barrier changes during diabetic
nephropathy. (A) Normal glomerular filtration barrier. (B) Diabetic kidney. GBM:
glomerular basement membrane; SD: slit diaphragm. Modified from Suh and Miner, 2013.
2.4.2.2 Tubular changes
     Development of progressive renal dysfunction in DN involves changes in the renal
tubules. The changes usually develop before the onset of macroalbuminuria. Tubular
hypertrophy, thickening of the tubular basement membrane, and tubular apoptosis may be
present in DN (Brito et al., 1998).
2.4.2.3 Interstitial changes
     The interstitium of the kidney comprises the extravascular intertubular spaces of the
kidney and is bounded on all sides by tubular and vascular basement membranes. In diabetic
kidneys, the interstitial fibrosis follows glomerular changes and is proportional to tubular
atrophy (Mauer et al., 1984).
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2.4.2.4 Vascular changes
     Hyalinosis  of  afferent  and  efferent  arterioles  is  also  a  typical  lesion  in  DN.  However,
hyalinosis  of  efferent  arterioles  is  specific  for  DN  and  distinct  from  other  kidney  diseases
(Stout et al., 1994). Besides characteristic arteriolar hyalinosis, the presence of large vessels
and arteriosclerosis may be observed in biopsy.
2.4.3 Mechanisms associated with the development of diabetic nephropathy
     The factors involved in the pathogenesis of DN are multifaceted. Age, gender, age at onset
of diabetes, poor glycemic control, smoking, dyslipidemia, and metabolic syndrome are risk
factors of DN. Genetic susceptibility is also linked to this disease (reviewed in Harjutsalo and
Groop, 2014). Two major factors, hemodynamic (glomerular hypertension) and metabolic
(hyperglycemia), contribute to the development and progression of DKD. Hyperglycemia
causes kidney damage through four major mechanisms. It leads to formation of advanced
glycated end-products (AGEs) via irreversible nonenzymatic glycation of proteins and lipids
that  bind  to  a  specific  cell  surface  receptor  for  AGE  (RAGE),  leading  to  production  of
reactive oxygen species (ROS). Increase in protein kinase C (PKC) activation results in
activation of growth factors and decreased production of endothelial nitric oxide (NO).
Increased activity of polyol pathways leads to conversion of glucose to sorbitol by aldose
reductase and further, reduced nicotinamide adenine dinucleotide phosphate (NADPH)
oxidase. Hexosamine pathway activity, elevated in hyperglycemic conditions, increases the
expression of growth factors at the mRNA level. Hemodynamic pathways include elevations
of systemic and intraglomerular pressure and activation of various vasoactive hormone
pathways, including the renin-angiotensin aldosterone system (RAAS), endothelin, and
urotensin. RAAS is the major controller of blood pressure. Renin converts angiotensinogen to
angiotensin I, which is further converted by angiotensin-converting enzyme to angiotensin II.
The latter is the key promoter of vascular damage (reviewed in Brownlee et at., 2001;
reviewed in Soldatos and Cooper, 2008). In patients with T1DM hypertension is associated
with DN (Hasslacher et al., 1985) and aggressive treatment of hypertension improves kidney
function (Parving et al., 1983).
     The altered hemodynamic pathways act independently and in concert with metabolic
pathways to activate intracellular secondary messengers such as PKC, mitogen-activated
protein kinase (MAPK), nuclear transcription factors such as nuclear factor-κB (NF-κB) and
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various growth factors such as the prosclerotic cytokines, transforming growth factor-β1
(TGF-β1), connective tissue growth factor (CTGF) and the angiogenic, permeability
enhancing growth factor, vascular endothelial growth factor (VEGF) (reviewed in Brownlee
et at., 2001; reviewed in Soldatos and Cooper, 2008). These growth factors have been
implicated in modulation of the immune system and activation of enzymes involved in
glucose metabolism.
     Inflammation is an important factor implicated in the pathogenesis of DN. Inflammatory
cytokines, mainly IL-1, IL-6, IL-18, as well as TNF-α are involved in this process. The renal
cortical mRNA expression of IL-1, IL-6 and TNF-α were found to be upregulated in
experimental  diabetes (Navarro et  al.,  2006).  In addition, IL-6 was shown to be elevated in
plasma from T1DM and T2DM patients and has been associated with albuminuria (Myrup et
al., 1996; Pickup et al., 2000; Saraheimo et al., 2003). Overexpression of IL-18 was reported
in human tubular epithelial cells in patients with DN (Miyauchi et al., 2009). Elevated IL-18
levels in both serum and urine were also shown to be directly and strongly associated with the
AER (Nakamura et al., 2005). Hyperglycemia promotes chronic inflammation also via NF-
ĸB. Activation of NF-ĸB by PKC (Yerneni et al., 1999) and RAGE (Lander et al., 1997) was
observed  in  diabetes  (Bierhaus  et  al.,  2001).  C-reactive  protein  (CRP)  was  shown  to  be
elevated in patients with T1DM and associates with the increased AER (Schalkwijk et al.,
1999).
     Dyslipidemia has also been pointed out as a pathophysiological factor in the development
of DN, as it was found to parallel with DKD (Tolonen et al., 2008). In T1DM subjects, low
high density cholesterol (HDL) and elevated triglycerides associate with obesity, which has
also been linked to DN (Iseki et al., 2004). Hyperinsulinemia also plays a role by increasing
glomerular capillary pressure and glomerular hyperfiltration, endothelial dysfunction and
increased vascular permeability (reviewed in Groop et al., 2005). Furthermore, insulin
resistance not only parallels but also precedes the development of DN in T1DM patients (Yip
et al., 1993). In combination, all of these factors increase AER, extracellular matrix
accumulation, cell hypertrophy, and apoptosis (Figure 5).
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Figure 5. An overview of the pathogenic mechanisms involved in the development of
diabetic nephropathy. AGE: advanced glycation end products; ECM: extracellular matrix;
MAPK: mitogen-activated protein kinase; NF-ĸB: nuclear factor kappa-light-chain-enhancer
of activated B cells; PKC: protein kinase C; RAAS: renin-angiotensin-aldosterone system.
2.5 Animal models of diabetic kidney disease
     Animal models of DKD are keys to understanding disease pathogenesis and to developing
rational treatment strategies. There are, however, important anatomical and functional
distinctions between animals and humans. Experimental models of diabetes only partially
reproduce the pathophysiological and histological changes characteristic of human DN (Rees
and Alcolado, 2005). Histological changes (glomerulosclerosis and Kimmelsteil–Wilson
nodules) are generally much less severe in animal models than those seen in humans. The
severity of glomerulosclerosis in rodent models varies considerably within species,
suggesting that the genetic background independently affects the disease process. Declining
glomerular filtration rate is often not seen. Perhaps the lack of some of these features in the
models reflects the fact that human DN can take decades to develop, and it seems likely that
their absence is due to the relatively short lifespan of the mice or rats (reviewed in King,
2012). However, rodent models remain the most popular species to approximate human
disease. There has been a progressive increase in studies using mouse models, with a
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corresponding decrease in the use of rats (Brosius et al., 2009). The large number of rodent
models of DKD include artificially induced, spontaneously mutated and genetically
engineered (knockout or transgenic) models.
2.5.1 Streptozotocin-induced diabetic rats
     Streptozotocin (stz) model represents an artificially induced model for T1DM. Stz is a
glucose analogue that enters insulin-producing β-cells in pancreas via glucose transporter 2
(GLUT2) and destroys the cells by acute necrosis or inflammatory reaction (Like and
Rossini, 1976; Tesch and Allen, 2007), leading to T1DM. Stz is typically used to induce
diabetes in mice, Sprague-Dawley or Wistar-Kyoto rats. Repeated doses are needed in mice
to  achieve  diabetes  (Siu  et  al.,  2006).  High  doses  of  stz  may  result  in  a  direct  nephrotoxic
effect and interfere with the hyperglycemia-induced kidney disease (Tay et al., 2005).
Multiple low doses of stz are given to mice, which induces repetitive b-cell damage.
However, with multiple low doses the level of albuminuria remains lower as a result of
reduced direct nephrotoxicity of stz.
2.5.2 Zucker rats
     Obese Zucker rats (fa/fa rats) are the spontaneous mutated model for T2DM. The rats have
a missense mutation in the leptin receptor gene (fa/fa) (Chua et al., 1996). The rats exhibit
physiological and metabolic similarities to human T2DM including insulin resistance,
hyperlipidemia, hypertension and obesity. Hyperglycemia manifests by 12 weeks. Renal
abnormalities, manifested as FSGS, mesangial matrix expansion and albuminuria develop
late (Coimbra et al., 2000).
2.6 Podocytes in diabetes
Podocyte architecture and function are changed in both T1DM and T2DM (Bjorn et al.,
1995; Pagtalunan et al., 1997; White et al., 2004). During disease progression, widening of
the foot processes (Bjorn et al., 1995) and podocyte detachment and loss (Pagtalunan et al.,
1997; White et al., 2004) become more marked and correlate with the level of proteinuria
(Bjorn et al., 1995; White et al., 2002). Effacement is a well-described finding in DN and it
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results from the disruption of the SD complex, changes in the foot process-GBM interaction
and changes in the negatively charged apical domain of the podocytes. Effacement can also
be caused by direct interference with the actin cytoskeleton (Smoyer et al., 1997; Ha, 2006).
2.6.1 Podocyte loss
     The podocyte number is significantly reduced already early in diabetes (Pagtalunan et al.,
1997; Steffes et al., 2001; White et al., 2002), and reduction in the number of podocytes
correlates with increased AER and predicts progression of albuminuria (Meyer et al., 1999;
White et al., 2002; White et al., 2004). Podocytes have been also reported in the urine of 53%
of diabetic patients with microalbuminuria and in 80% of those with macroalbuminuria
(Nakamura et al., 2000).
     Hyperglycemia plays a role in podocyte loss through a number of diverse mechanisms.
ROS were shown to induce podocyte apoptosis via activation of proapoptotic p38 MAPK and
caspase-3 in cultured podocytes and in mouse models of diabetes (Susztak et al., 2006). In
addition, TGF-β1 can induce MAPK mediated podocyte loss (Schiffer et al., 2001).
Furthermore, high glucose activates RAAS and increased level of angiotensin II has been
shown to promote podocyte apoptosis (Ding et al., 2002).
     Activation of the PI3K/AKT via nephrin protects against podocyte apoptosis (Huber et al.,
2003), and failure in AKT phosphorylation causes apoptosis in db/db mice (Tejada et al.,
2008).
2.6.2 Podocyte foot process effacement
     Podocyte foot process effacement could be caused by changes in SD-associated proteins,
interference with the GBM or podocyte-GBM interaction, actin cytoskeleton abnormalities,
or alterations in the negative apical membrane domain of podocytes (reviewed in Mundel and
Shankland, 2002).
     In T1DM and T2DM patients with micro- and macroalbuminuria, nephrin has been
detected in urine (Patari et al., 2003). Loss of nephrin mRNA and protein in podocytes
correlates with proteinuria and increased foot process widening (Langham et al., 2002; Koop
et al., 2003; Benigni et al., 2004). Downregulation of nephrin expression has also been
reported also in streptozotocin-induced diabetic rats and in the nonobese diabetic mouse
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(Aaltonen et al., 2001; Forbes et al., 2002). Moreover, in streptozotocin-induced T1DM rats,
nephrin protein was also found in the urine (Aaltonen et al., 2001).
     In human and experimental models of diabetes expression of α3β1-integrin is decreased
(Regoli and Bendayan, 1997; Chen et al., 2006). The suppression progresses with diabetes
duration and may be involved in podocyte loss by detachment (Regoli and Bendayan, 1997;
Chen et al., 2000).
    Studies have also shown that the expression of podocalyxin is reduced in podocytes
exposed to high glucose and in streptozotocin-induced T1DM rats (Qi et al., 2007; Fang et
al., 2013).
2.7 Role of kidneys in maintaining glucose homeostasis
     Despite daily fluctuations, plasma glucose is normally maintained within a narrow
range (4-9 mM). The human kidney is involved in the regulation of glucose homeostasis.
Under normal conditions, glucose filtered by glomeruli is completely reabsorbed, but under
hyperglycemic conditions glucosuria may occur.
2.7.1 Role of kidneys in the regulation of glucose homeostasis
     The mechanisms involved in the regulation of glucose homeostasis by the kidney include
glucose release via gluconeogenesis, glucose uptake from the circulation and glucose
reabsorption from the glomerular filtrate. About 10 to 15 % of the daily glucose intake that
circulates in the body is used by the kidneys (Gerich, 1993). Glucose utilization is restricted
mostly to the kidney medulla and glucose release occurs in the kidney cortex (Guder and
Ross, 1984; Wirthensohn and Guder, 1986; Schoolwerth et al., 1988). Renal glucose release
is stimulated by catecholamines (Stumvoll et al., 1995) and suppressed by insulin (Meyer et
al., 1998a). In the postabsorptive state, after overnight fasting, the kidneys contribute to
around 20% of the overall glucose release (Stumvoll et al., 1995; Ekberg et al., 1999; Moller
et al., 2001). Surprisingly, in the postprandial state, kidney gluconeogenesis increases by
twofold (Meyer et al., 2002).
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2.7.2 Glucose homeostasis in the kidney in diabetes mellitus
     Patients with T2DM dispaly increased renal glucose release in postabsorptive and
postprandial states compared to healthy individuals (Meyer et al., 1998b; Meyer et al., 2004).
As insulin resistance is present in diabetic patients, the process of renal glucose release is
resistant to suppression by insulin. Furthermore, in T2DM subjects receiving overnight
insulin infusions, renal glucose release remains increased as in patients with diabetes without
infusion (Woerle et al., 2002).
     Glucose uptake by the kidney is also greater in both postabsorptive and postprandial states
in patients with T2DM (Meyer et al., 1998b; Meyer et al., 2004). Renal glucose reabsorption
from  the  glomerular  filtrate  is  also  higher  in  those  subjects  (Mogensen,  1971).  The  kidney
therefore contributes to the fasting and postprandial hyperglycemia in T2DM patients.
2.8 Molecular mechanisms regulating glucose transport into podocytes
    Activation of the IR by insulin leads to a cascade of signaling events that coordinate
translocation of the GSV to the plasma membrane and glucose uptake into podocytes.
Glucose uptake is achieved through the facilitative glucose transporters GLUT1 and GLUT4.
The PI3K and the cGMP-dependent protein kinase G signaling pathways are implicated in
the regulation of the GSV trafficking in podocytes. GSV translocation occurs in multiple
stages including approaching, tethering, docking and fusion.
2.8.1 Insulin signaling pathways
Podocytes are insulin-responsive cells (Coward et al., 2005). Similar to adipocytes and
muscle cells, they respond to insulin by activating the PI3K and MAPK signaling pathways.
Insulin can also activate CAP (Cbl-associated protein)/c-Cbl pathway in adipocytes but not in
podocytes or muscle cells (Welsh et al., 2010). PI3K is implicated in glucose uptake by
inducing the translocation of glucose transporters to the plasma membrane. Another signaling
pathway that appears to stimulate glucose uptake in podocytes is the cGMP-dependent
protein kinase G (PKG) pathway (Piwkowska et al., 2014). The MAPK signaling pathway
does not mediate the metabolic action of insulin in this cell type, but is involved in
proliferation, transcriptional regulation of various target genes, and production of cytokines
(reviewed in Tian et al., 2000) (Figure 6).
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2.8.1.1 Insulin receptor and its substrates
The IR is a heterotetrameric complex, consisting of two extracellular α subunits that bind
insulin,  and  two  transmembrane  β subunits  with  tyrosine  kinase  activity  (Lee  and  Pilch,
1994).  The  IR  exists  in  two  forms,  A  and  B.  IR-A  is  ubiquitously  expressed  and  IR-B  is
expressed in insulin-sensitive tissues such as liver, muscle, adipose tissue, and kidney.
Binding of insulin to IR leads to autophosphorylation of its tyrosine residues. This results in
increased catalytic activity of the tyrosine kinase, which further phosphorylates tyrosine
residues on the insulin receptor substrate-1 (IRS-1) (Ullrich et al., 1985). Upon
phosphorylation, IRS-1 activates PI3K and MAPK pathways.
2.8.1.2 The phosphatidylinositol 3-kinase signaling pathway
Upon tyrosine phosphorylation, IRS proteins interact with the p85 regulatory subunit of
the PI3K, which leads to its activation and translocation to the plasma membrane. The
enzyme catalyzes the phosphorylation of phosphatidylinositol 4,5-bisphosphate (PIP2) to
form phosphatidylinositol 3,4,5-trisphosphate (PIP3). Insulin-stimulated increases in PIP3
result in the phosphorylation and activation of AKT. The negative regulators of PI3K include
protein phosphatases that dephosphorylate IRS-1 (Elchebly et al., 1999), as well as lipid
phosphatases SHIP2 (SH2-domain-containing inositol polyphosphate-5 phosphatase 2) and
phosphatase and tensin homolog (PTEN) (Vinciguerra and Foti, 2006).
2.8.1.3 The cGMP-dependent protein kinase G signaling pathway
     cGMP-dependent  protein  kinase  G  type  I  (PKG-I)  is  a  homodimer  comprised  of  two
identical subunits, which are found as two isoforms, Iα and Iβ (Hofmann et al., 2009).
Dimerization of two PKG-I subunits increases its catalytic activity, and consequently its
biological action. The PKG-Iα isoform is expressed in cultured rat podocytes (Piwkowska et
al., 2012; Piwkowska et al., 2013), in which PKG-I activators, including insulin and
hydrogen peroxide, regulate insulin signaling pathways via increased phosphorylation of IR
and AKT. This enhances GLUT4 translocation to the plasma membrane and glucose uptake
(Piwkowska et al., 2014).
35
Figure 6. Schematic structure of the insulin signaling pathway in podocytes. GSV:
GLUT4 storage vesicle; IRS-1: insulin receptor substrate-1; MAPK: mitogen-activated
protein kinase; PDK-1: phosphoinositide-dependent kinase 1; PI3K: phosphatidylinositol 3-
kinase; PKG-I: cGMP-dependent protein kinase G type I.
2.8.2 Glucose transporters in the kidney
     The facilitative glucose transporter family includes 13 members (Devaskar and Mueckler,
1992), most of which catalyse the transport of glucose down its concentration gradient across
the plasma membrane. In the kidney, GLUT1, GLUT3, and GLUT4 are expressed in
mesangial cells and podocytes (Brosius et al., 1992; Heilig et al., 1995; Coward et al., 2005;
Lewko and Stepinski, 2009). GLUT1 appears to be the predominant transporter in cultured
mesangial cells (Li et al., 2001). GLUT2 is known to be expressed in podocytes (Lewko and
Stepinski, 2009) and GLUT8 is present in podocytes and tubular cells (Schiffer et al., 2005).
2.8.3 Mechanisms of glucose uptake into podocytes
          GLUT4 is the major insulin-inducible glucose transporter. In the basal state, GLUT4 is
preferentially located in perinuclear depots and to a lesser extent in cytosolic vesicles and the
plasma membrane. However, after insulin stimulation, it is mainly found in vesicles (GSVs)
that translocate to the plasma membrane (reviewed in Stöckli et al., 2011). GSV trafficking
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consists of several steps. The first step involves the actin and microtubule-based cytoskeleton
in the approach of GSVs to the plasma membrane. The second step includes two processes:
tethering and docking. The exocyst complex proteins help tether the GSVs to the plasma
membrane, and docking is mediated by assembly of the SNARE complex. The last step of
GSV trafficking to the cell surface is fusion, in which a specific interaction between v-
SNARE  and  t-SNARE  proteins  allows  merging  of  the  lipid  bilayers  of  the  GSVs  and  the
plasma membrane (Figure 7).
     Mechanisms that regulate GSV trafficking and glucose uptake into podocytes are not well
defined. GLUT1 and GLUT4 are known to mediate insulin-stimulated glucose uptake into
cultured human podocytes, and GLUT1 also affects basal glucose uptake (Coward et al.,
2005). GLUT2 and GLUT4 were described to mediate glucose uptake in cultured rat
podocytes (Lewko et al., 2005). In human podocytes, GLUT4 translocation was shown to be
dependent on the actin cytoskeleton (Coward et al., 2005). Furthermore, nephrin is important
for the insulin-stimulated fusion of GLUT1 and GLUT4 vesicles with the plasma membrane
through  its  interaction  with  VAMP2  (Coward  et  al.,  2007).  A  recent  study  showed  that
phosphorylation of synip is required for its dissociation from syntaxin 4 and insulin-
stimulated GLUT4 translocation and glucose uptake into podocytes (Yamada et al., 2014).
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Figure  7.  Overview  of  the  steps  involved  in  GLUT4  storage  vesicle  trafficking  to  the
plasma membrane. Insulin-stimulated translocation of GLUT4 storage vesicles (GSV)
consists of multiple steps. The first step involves approaching of GSVs from an intracellular
location close to the cell surface after insulin stimulation. The second step, tethering, involves
the exocyst complex which plays a role in the low-affinity interaction of GSVs with the
plasma membrane. The last steps are docking, a high-affinity interaction of GSVs with the
plasma membrane, and fusion, a merging of the lipid bilayers of the GSVs and the plasma
membrane. The docking and fusion require formation of the ternary complex between v-
SNARE,  VAMP2,  on  the  GSV  and  t-SNAREs,  syntaxin-4  and  SNAP23,  on  the  plasma
membrane.
2.9 Role of insulin resistance in the pathogenesis of diabetic nephropathy
     Insulin resistance of podocytes may be an important initiator for many of the pathological
processes observed in DN.
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2.9.1 Mechanisms of insulin resistance
2.9.1.1 Hyperglycemia
     Excess intracellular glucose induces AGE production, which in turn impairs PI3K-
dependent insulin signaling (Miele et al., 2003). Moreover, hyperglycemia results in insulin
resistance via mechanisms involving oxidative stress and ROS production by NADPH
oxidase (reviewed in Brownlee, 2001). Studies have shown that activation of the AMP-
activated protein kinase (AMPK) increases glucose transport and could have a beneficial
effect in preventing insulin resistance (Tomas et al., 2002).
2.9.1.2 Free fatty acids
     Similar  to  high  glucose,  free  fatty  acids  (FFA)  also  stimulate  ROS  production  through
PKC-dependent activation of NADPH oxidase (Inoguchi et al., 2000). FFA were shown to be
released from adipose tissue and their concentration is elevated in the insulin resistant state
(Golay et al., 1986). Increased FFA inhibits insulin signaling and glucose uptake in muscle
(Roden et al., 1996) and activates the PKC and NF-ĸB pathways (Itani et al., 2002).
2.9.1.3 Inflammation
     Inflammation correlates with insulin resistance and adiposity in human patients with
T2DM (Leinonen et al., 2003). Adipokines, secreted by adipose tissue, have both stimulating
and inhibitory roles on insulin sensitivity. Proinflammatory cytokines including TNF-α and
IL-6 are secreted by adipocytes and further promote peripheral insulin resistance. Infusion of
TNF-α results in the development of insulin resistance in the skeletal muscle of healthy
humans by leading to impaired AKT phosphorylation and dysfunction in glucose uptake
(Plomgaard et al., 2005). Furthermore, TNF-α stimulates FFA release (Plomgaard et al.,
2008). IL-6 also inhibits insulin signaling by interfering with the IR and IRS-1 (Senn et al.,
2002). In contrast, leptin and adiponectin mediate insulin-sensitizing actions in peripheral
tissues (reviewed in Beale, 2013).
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2.9.2 Insulin resistance in kidney dysfunction
     Several pieces of evidence suggest that reduced insulin action can affect kidney function.
Insulin  resistance  plays  a  significant  role  in  the  pathogenesis  of  DN.  A  large  number  of
epidemiological studies have reported the association between insulin resistance and kidney
dysfunction in both non-diabetic and diabetic subjects. In fact, the podocyte IR knockout
mouse develops podocyte apoptosis, effacement of foot processes, thickening of the GBM,
and increased glomerulosclerosis and albuminuria.
2.9.2.1 The correlation of insulin resistance and diabetic nephropathy
     Insulin resistance correlates with microalbuminuria in non-diabetic (Mykkanen et al.,
1998), T1DM (Yip et al., 1993) and T2DM subjects (Groop et al., 1993; Forsblom et al.,
1995; Parvanova et al., 2006), independent of blood pressure (Groop et al., 1993). This
suggests that insulin resistance alone can lead to the development of microalbuminuria.
Based on the data from patients with diabetes (Miyazaki et al., 2007) and from animal models
(Zhang et al., 2008), insulin sensitizers have a renoprotective effect. This further supports the
hypothesis of a pathogenic role of insulin resistance in DN.
2.9.2.2 Podocytes and insulin resistance
     Insulin resistance of podocytes was first demonstrated in early diabetes in T2DM db/db
mice (Tejada et al., 2008). In the same model, IR and PI3K signaling were lost in podocytes
(Tejada et al., 2008). A similar loss of insulin signaling via PI3K was found in the glomeruli
of T1DM streptozotocin rats and T2DM Zucker rats (Mima et al., 2011). Podocyte-specific
IR knockout mice develop albuminuria and histological features of DN even in the setting of
normoglycemia (Welsh et al., 2010). Interestingly, the podocyte protein nephrin is crucial for
the insulin sensitivity of podocytes as measured by glucose uptake (Coward et al., 2007), and
its expression was shown to be reduced in early DN (Doublier et al., 2003; Patari et al., 2003;
Jim et al., 2012).
     The role of adiponectin and cathepsin L in the development of podocyte insulin resistance
may also be considered. Adiponectin may have a protective effect on podocytes via
stimulation of the AMPK pathway and reduced oxidative stress, as well as modulation of
glucose uptake into podocytes. Podocytes isolated from db/db mice showed decreased
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expression of adiponectin receptor 1 and 2 (Kadowaki et al., 2006; Sharma et al., 2008).
Further, cathepsin L, which is associated with the degradation of the IR subunit β, is
upregulated in diabetic glomeruli (Yang et al., 2007; Sever et al., 2007).
     Studies  have  shown  that  in  glomeruli  of  db/db  mice,  upregulation  of  JNK,  a  negative
regulator of insulin signaling, may result in the inability of podocytes to respond to insulin
(Ijaz et al., 2009). In cultured human podocytes, the free fatty acid palmitate induces insulin
resistance via reduced glucose uptake and reduced phosphorylation of IRS-1 and AKT
(Lennon et al., 2009). Lipid phosphatase SHIP2 was shown to downregulate insulin response
by reducing AKT activation in cultured human podocytes. Further, SHIP2 expression was
found to be elevated in glomeruli of insulin resistant obese Zucker rats (Hyvönen et al.,
2010).
2.9.3 Glucose transporters in diabetic nephropathy
     Individual glucose transporters may affect podocyte function. GLUT1 expression was
shown to be elevated in cultured human podocytes exposed to high glucose (Moutzouris et
al., 2007). Similar changes were observed in mesangial cells exposed to high glucose in vitro
and was associated with increased glucose uptake (Heilig et al., 1997) and stimulated
production of extracellular matrix proteins (Heilig et al., 1995). Upregulation of GLUT1 was
also described in glomeruli of streptozotocin–induced T1DM rats (D’Agora et al., 2001) and
in T2DM db/db mice (Chen et al., 2003). Overexpression of GLUT1 in glomerular mesangial
cells in mice mimics typical features of diabetic glomerular disease, without diabetes or
hypertension (Wang et al., 2010). The data suggest that GLUT1 may play an important role
in the development of DKD. However, the role of GLUT1 appears to vary depending on the
cell type, as podocyte-specific overexpression of GLUT1 in diabetic mice reduces mesangial
expansion (Zhang et al., 2010).
     Chronic exposure of cultured human podocytes to high glucose reduced GLUT4
expression (Moutzouris et al., 2007). GLUT4 expression was also shown to be upregulated,
and GLUT1 downregulated, in the glomeruli of normoalbuminuric T1DM patients and db/db
mice (Guzman et al., 2014). However, glomeruli from T1DM patients with microalbuminuria
and microalbuminuric db/db mice presented decreased GLUT4 and increased GLUT1
expression (Guzman et al., 2014). Furthermore, podocyte-specific GLUT4-deficient mice are
protected from diabetes-induced podocyte hypertrophy, mesangial expansion, and
41
albuminuria (Guzman et al., 2014). This suggests that decreasing GLUT4 expression or
attenuating its function may be beneficial in proteinuric kidney diseases.
     In addition, GLUT3 was shown to be upregulated in human podocytes exposed to high
glucose in vitro (Moutzouris et al., 2007), and GLUT8 expression levels was higher in
podocytes of kidneys of diabetic db/db mice compared with nondiabetic mice (Schiffer et al.,
2005). More studies will be required to elucidate the mechanisms of glucose transporter
modulation in podocytes to provide further insight into their role in the pathogenesis of DN.
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3 AIMS OF THE STUDY
     The mechanisms leading to the development of DN are not fully understood, but podocyte
damage is involved. Therefore, a more detailed characterization of the early
pathophysiological changes in glomeruli is essential to deepen our knowledge of podocyte
injury and the mechanisms behind the development of DN. Interestingly, with respect to
glucose uptake, podocytes are uniquely insulin sensitive cells in the glomerulus and are able
to absorb glucose via translocation of glucose transporters to the plasma membrane.
Furthermore, recent data show that insulin signaling is essential for normal kidney function.
     Defects in the trafficking of the glucose transporters may affect the insulin sensitivity of
podocytes. Therefore, regulators of glucose transporter trafficking may provide suitable
targets to enhance the insulin sensitivity of podocytes and prevent the development and
progression of DN. The molecular mechanisms that regulate glucose uptake into podocytes
are poorly characterized, but it has been shown that insulin-stimulated glucose uptake into
podocytes depends on the podocyte protein nephrin. This thesis sought to characterize the
early pathophysiological mechanisms leading to glomerular podocyte injury in DN, and to
obtain a better understanding of the mechanisms of how glucose transporter trafficking,
docking, and fusion are regulated in podocytes.
The specific objectives of this thesis work were the following:
I. To identify changes in the expression of glomerular proteins at  an early stage of
DN by comparative proteomics and to investigate the role of ezrin in regulating
glucose transporter trafficking in podocytes.
II. To investigate the role of septin 7, a novel CD2AP and nephrin interaction
partner, in podocytes.
III. To characterize the role of septin 7 and its interaction partner, nonmuscle myosin
heavy chain IIA, in the regulation of glucose transporter trafficking in podocytes.
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4 MATERIALS AND METHODS
4.1 Experimental animals
4.1.1 Sprague-Dawley rats
     The kidneys of Sprague-Dawley rats were used to investigate the expression, localization,
and interactions of proteins (Studies I-III).
4.1.2 Streptozotocin rats
     Male Sprague-Dawley rats (Toxi-coop, Dunakeszi, Hungary) were injected
intraperitoneally  with  streptozotocin  (stz)  (Sigma-Aldrich,  St.  Louis,  MO,  USA).
Development of diabetes was confirmed by an oral glucose tolerance test one week after stz
injection and at sacrifice four weeks after stz injection. Urine was collected and urinary
albumin was measured by a rat albumin-specific ELISA kit (Immunology Consultants
Laboratory Inc, Portland, OR, USA). Animal procedures were approved by the Animal Care
and Use Committee of the Semmelweis University (Study I).
4.1.3 Zucker rats
     Obese (fa/fa) and lean (fa/+) Zucker rats (Crl:ZUC-Leprfa) were purchased from Charles
River Laboratories (Sulzfeld, Germany). Blood glucose, urinary albumin, and creatinine
measurements have been described in (Hyvönen et al., 2010). Animal work was approved by
the national Animal Experimental Board (Studies I and III).
4.2  Human study subjects
4.2.1 Human kidney samples
     Kidney samples of renal cancer patients with or without T2DM were obtained from
surgical nephrectomies performed for diagnostic purposes at Helsinki and Uusimaa Hospital
district, and were from the nonmalignant part of the kidney. Albuminuria, the clinical sign of
44
DN, was determined from the medical records. The use of human material was approved by
the local Ethics Committee (Studies I and III).
4.2.2 Human sera
     Serum samples were obtained from 4 healthy controls and 5 patients with T2DM from the
Finnish Diabetic Nephropathy Study (FinnDiane). Urinary AER was defined as normal (<30
mg/24 h), microalbuminuria (≥30, <300 mg/24 h), and macroalbuminuria (≥300 mg/24 h).
Fasting glucose values were measured using a Hemocue device (Hemocue, Helsinki,
Finland), and serum lipids were determined with a Konelab analyzer (Thermo Scientific,
Vantaa, Finland). Other biochemical analyses were performed in an accredited hospital
laboratory (HUSLAB, Helsinki, Finland). The use of human material was approved by the
local Ethics Committee (Study III).
4.3  Cell culture
     Several cell lines were used in this thesis work to investigate the expression, protein-
protein interactions, and functions of ezrin, septin 7, and nonmuscle myosin heavy chain IIA.
The cell lines used and their culture media are shown in Table 1. Mouse podocytes were
maintained in 5% CO2 at 33°C. Human podocytes were cultured in 5% CO2 at 33°C
(undifferentiated podocytes) and shifted to 37°C for 14 days in 5% CO2 for differentiation.
HIRc (rat fibroblasts stably overexpressing human insulin receptor), HEK293, HEK293T and
HEK293FT cells were maintained in 5% CO2 at 37°C (Studies I-III). Cells were transfected
with  ON-TARGET  plus  SMARTpool  or  siCONTROL  Non-Targeting  Pool#2  siRNAs
(Dharmacon, Lafayette, CO, USA) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA,
USA) (Studies I-III). Mouse podocytes were transiently transfected with pcDNA 3.1-SEPT7
or pcDNA 3.1 as a control using Lipofectamine 2000 (Invitrogen) (Study III). HEK293T
cells were co-transfected with pLNCX2-nephrin and packaging pKAT2 vectors using
Lipofectamine 2000 (Invitrogen). Virus-containing medium was used to infect mouse
podocytes  (Study  III).  In  some  studies,  human  podocytes  were  treated  with  5  µM
cytochalasin D (Sigma-Aldrich) for 30 min (Study II), and HIRc cells and mouse podocytes
were treated with 50 µM forchlorfenuron (FCF) (Sigma-Aldrich) for 4 h (Study II).
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Cell line Culture media                            Reference / supplier Study
Wild-type and
CD2AP KO mouse
podocytes
DMEM medium containing 4.5 g/L
glucose supplemented with L-
glutamine, 10% fetal calf serum,
penicillin and streptomycin
Schiffer et al., 2004 I, III
Human podocytes
RPMI 1640 medium containing
L-glutamine supplemented with 10%
fetal calf serum and insulin,
transferrin and selenite
Saleem et al., 2002 II
HIRc
DMEM medium containing 1 g/L
glucose supplemented with L-
glutamine, 10% fetal calf serum,
penicillin and streptomycin
McClain et al., 1987 II
HEK293,
HEK293T,
HEK293FT
DMEM medium containing 4.5 g/L
glucose supplemented with L-
glutamine, 10% fetal calf serum,
penicillin and streptomycin
ATCC II, III
Table 1. Cell lines used in Studies I-III.
    4.4 Antibodies
     The primary and secondary antibodies used in Studies I-III are presented in Table 2 and
Table 3.
Antibody Description Reference / supplier Study
ezrin (3C12) mouse monoclonal Bohling et al., 1996 I
phosphorylated
ezrin rabbit polyclonal
Santa Cruz Biotechnology
(Santa Cruz, CA, USA) I
NHERF2 rabbit polyclonal kindly provided by Dr. Peijian He(Emory University, Atlanta, GA, USA) I
moesin rabbit polyclonal AbD Serotec (Oxford, UK) I
podocin rabbit polyclonal Sigma-Aldrich I
podocalyxin rabbit polyclonal Miettinen et al., 1990 I
cofilin-1 rabbit polyclonal Abcam (Cambridge, UK) I
phosphorylated
cofilin-1 (Ser3) rabbit monoclonal
Cell Signaling Technology
(Denvers, MA, USA) I
septin 7 (N12) goat polyclonal Santa Cruz Biotechnology II, III
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septin 7 (H120) rabbit polyclonal Santa Cruz Biotechnology II, III
septin 7 (C) rabbit polyclonal Immuno-Biological Laboratories Co.,Ltd. (Gumma, Japan) II, III
septin 9 rabbit polyclonal kindly provided by Koh-ichi Nagata(Aichi Human Service Center, Japan) II
septin 11 rabbit polyclonal kindly provided by Koh-ichi Nagata II
CD2AP 209 rabbit polyclonal Lehtonen et al., 2008 II
CD2AP 211 rabbit polyclonal Lehtonen et al., 2008 II
CD2AP 1774 rabbit polyclonal Lehtonen et al., 2000 II
nephrin #1034 rabbit polyclonal Ahola et al., 2003 II, III
nephrin guinea pigpolyclonal
PROGEN Biotechnik
(Heidelberg, Germany) II, III
nephrin mouse polyclonal Topham et al., 1999 III
Pan AKT mouse monoclonal R&D Systems(Minneapolis, MN, USA) II
phosphorylated
AKT (Ser473) rabbit polyclonal Cell Signaling Technology II
nonmuscle myosin
IIA heavy chain rabbit polyclonal
Biomedical Technologies Ins.
(Stoughton, MA, USA) III
phosphorylated
myosin IIA heavy
chain (Ser1943)
rabbit polyclonal ECM Bioscience(Versailles, KY, USA) III
phosphorylated
myosin light chain 2
(Thr18/Ser19)
rabbit polyclonal Cell Signaling Technology III
GLUT1 rabbit polyclonal Millipore (Billerica, MA, USA) I
GLUT4 rabbit polyclonal Abcam I, II
SNAP23 rabbit polyclonal Synaptic System(Goettingen, Germany) III
SNAP23 mouse monoclonal Sigma-Aldrich III
syntaxin 4 rabbit polyclonal Sigma-Aldrich II, III
VAMP2 mouse monoclonal Synaptic System II, III
actin mouse monoclonal Sigma-Aldrich I-III
tubulin mouse monoclonal Sigma-Aldrich I-III
Table 2. Primary antibodies used in Studies I-III.
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Antibody Description Supplier Study
AlexaFluor 488 donkey anti-mouse Molecular Probes (LifeTechnologies, Carlsbad, CA, USA) I
AlexaFluor 488 donkey anti-goat Molecular Probes II
AlexaFluor 488 donkey anti-rabbit Molecular Probes II, III
AlexaFluor 555 donkey anti-mouse Molecular Probes I, III
AlexaFluor 555 donkey anti-rabbit Molecular Probes I, II
AlexaFluor 680 donkey anti-rabbit Invitrogen II
IRDye 680 donkey anti-mouse LI-COR (Lincoln, NE, USA) I-III
IRDye 800 donkey anti-rabbit LI-COR I-III
TrueBlot® HRP-conjugatedanti-mouse eBioscience (San Diego, CA, USA) II, III
TrueBlot® HRP-conjugatedanti-rabbit eBioscience II, III
TRITC-phalloidin F-actin staining Molecular Probes I, II
Table 3. Secondary antibodies used in Studies I-III.
4.5 Protein studies
4.5.1 Preparation of glomerular, tubular and cell lysates
     Glomeruli and tubules were isolated from rat kidney cortex using a graded sieving method
(sieves of decreasing pore sizes: 250 µm, 150 µm and 75 µm) (Orlando et al., 2001). Tubules
were  collected  from the  150  µm sieve  and  glomeruli  from the  75  µm sieve.  Glomeruli  and
tubules were lysed in 1% NP-40, 20 mM HEPES, pH 7.5, 150 mM NaCl. Cells were lysed in
1% NP-40, 20 mM HEPES, pH 7.5, 150 mM NaCl or 50mM HEPES, pH 7.6, 0.5% Triton X-
100, 0.5% CHAPS or 0.5% NP-40, 100 mM NaCl, 20 mM Tris-HCl, pH 8.0, 1 mM EDTA
by rotation at 4°C for 30 min. All buffers were supplemented with 1x Complete EDTA-free
proteinase inhibitor cocktail (Roche, Basel, Switzerland), 50 mM sodium fluoride and 1 mM
sodium orthovanadate. Detergent-insoluble material was removed by centrifugation (16 000 x
g at 4°C for 15 min), and the protein concentrations were measured by using a Bradford assay
(Studies I-III).
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4.5.2 Two-dimensional fluorescence difference gel electrophoresis (2D-DIGE)
     Rat glomeruli were isolated by graded sieving (Orlando et al., 2001), lysed in 7 mol/L
urea, 2 mol/L thiourea, 4% 3-[(3-cholamidopropyl)-dimethylammonio]- 1-propanesulfonate,
30 mmol/L Tris-HCl, pH 8.0, and 0.2% SDS, and sonicated. Protein concentrations were
measured using 2D Quant Kit (GE Healthcare, Chalfont St. Giles, UK). Glomerular lysates
from rats with streptozotocin-induced diabetes or controls, and an internal standard (a pool of
all samples) were labelled using CyDye DIGE Fluor minimal labeling kit (GE Healthcare).
Isoelectric focusing was performed with Immobiline™ DryStrips (GE Healthcare). Proteins
were resolved in polyacrylamide gels and imaged with Typhoon™ 9400 (GE Healthcare).
Spot detection, matching, and intensity-based quantitation were performed using DeCyder™
2D 7.0 software (GE Healthcare). Spots with at least 1.5-fold difference in expression
between control and streptozotocin-induced diabetic groups were considered differentially
expressed and significant (Study I).
4.5.3 Identification of proteins by LC-MS/MS
Proteins  were  detected  from  silver-stained  2D  SDS-PAGE  gel  (Study  I)  or  from  a
GelCode Blue (Pierce Chemical Co, Rockford, IL, USA) stained gel (Study III). Protein spots
of interest were in-gel digested with trypsin. The resulting peptides were analyzed by liquid
chromatography–tandem mass spectrometry (LC-MS/MS) as described previously (Ohman et
al., 2010). Database searches were done with Mascot (Matrix Science Ltd, London, UK)
through ProteinPilot 2.0 (Applied Biosystems/MDS SCIEX, Foster City, CA, USA) interface
against the SwissProt database via UniProt (http://www.uniprot.org). The search criteria
were: rodent-specific taxonomy (Study I) and human-specific taxonomy (Study III). All the
reported protein identification scores were statistically significant (p<0.05) (Studies I and III).
4.5.4 Immunoblotting
     Proteins were separated by SDS-polyacrylamide gels and transferred to PVDF membranes
(Millipore),  which  were  blocked  with  5%  skimmed  milk  or  with  Odyssey  blocking  buffer
(LI-COR). Membranes were incubated with specific primary antibodies, washed, and the
bound antibodies were detected using secondary antibodies conjugated with Alexa Fluor 680
49
(Invitrogen) or IRDye 680 or 800 (LI-COR). Blots were scanned and quantified using an
Odyssey Infrared Imaging System (LI-COR) (Studies I-III).
4.5.5 2-Deoxy-d-glucose uptake assay
     Mouse podocytes were serum-starved for 20 h and treated with or without 20 nM insulin
for 15 min in Krebs Ringer phosphate buffer (128 mM NaCl, 1.4 mM CaCl2, 1.4 mM
MgSO4, 5.2 mM KCl, 10 mM Na2HPO4, pH 7.4). HIRc cells were serum-starved for 16 h and
treated with or without 200 nM insulin for 15 min in Krebs Ringer phosphate buffer. Cells
were exposed to 50 μmol/l (1 μCi/ml) 2-deoxy-d-[(1, 2-3H(N)]-glucose (Perkin Elmer-Cetus,
Boston, MA, USA) for 5 min at 33°C (mouse podocytes) or 37°C (HIRc), washed with ice-
cold PBS, and solubilized in 1% Triton X-100 in PBS. β-Emission was measured by Wallac
1450 MicroBeta TriLux Liquid Scintillation Counter (Perkin Elmer-Cetus) (Studies I-III).
4.5.6 Protein interaction studies
4.5.6.1 Co-immunoprecipitation assay
     Rat glomeruli, human podocytes, or mouse podocytes were lysed as previously described.
Lysates were precleared with protein A or G Sepharose beads (Invitrogen or Zymed, South
San Francisco, CA, USA) or TrueBlot® anti-rabbit or anti-mouse Ig IP beads (eBiosciences)
and incubated overnight at 4°C with primary antibodies or purified rabbit or mouse IgGs
serving as controls. The antibody-protein complexes were captured to beads, and unbound
proteins were removed by washing with lysis buffer. Samples were boiled in Laemmli sample
buffer, separated by SDS-PAGE and immunoblotted (Studies II and III).
4.5.6.2 Production of GST-fusion proteins and pull-down assays
     GST, GST-CD2AP SH3 domains (Palmen et al., 2002), GST-nephrin (Lehtonen et al.,
2004) and GST-septin 7 fusion proteins covering different regions of the protein (Nagata et
al., 2004) were produced in E. coli BL21 (DE3) (Stratagene, La Jolla, CA, USA). The fusion
proteins were purified with glutathione-Sepharose beads (Invitrogen) and analyzed by SDS-
PAGE and Coomassie staining. Rat glomerular lysates were precleared with glutathione-
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Sepharose beads and incubated with GST-fusion proteins or GST on beads at 4°C for 4 h.
Beads were washed with lysis buffer, boiled in Laemmli buffer, separated by SDS-PAGE and
immunoblotted (Study II).
4.5.6.3 Duolink In Situ
     Interactions of SNAP23 with septin 7, nonmuscle myosin IIA, phosphorylated myosin
heavy chain, and phosphorylated myosin regulatory light chain were detected by the
proximity ligation assay kit Duolink: PLA probe anti-rabbit plus, PLA probe anti-mouse
minus (Olink Bioscience, Uppsala, Sweden). The samples were processed following the
manufacturer's instructions and the fluorescence images were captured using a Zeiss
Axioplan2 microscope (Carl Zeiss Microscopy, Thornwood, NY, USA). Quantification of the
detected PLA signals was performed using the DuoLink Image Tool (Olink Bioscience)
(Study III).
4.5.7 Subcellular fractionation
     Mouse podocytes were homogenized by passage through a 25G needle and the resulting
homogenate was centrifuged at 1000 x g, 4°C for 5 min to obtain post-nuclear supernatant
(PNS). The PNS was ultracentrifuged 100 000 x g at 4°C for 1 h using a SW55 Ti rotor to
obtain cytosol (S100) and membrane (P100) fractions. Equal volumes of the fractions were
separated in SDS-PAGE for immunoblotting (Study II).
4.6 Electron microscopy
     Kidney samples were fixed in 1.5% glutaraldehyde, 3% paraformaldehyde, 5% sucrose in
0.1  M  cacodylate  buffer,  pH  7.4,  at  room  temperature  for  2  h,  postfixed  in  1%  osmium
tetroxide  (OsO4)  in  the  same  buffer  for  1  h,  stained en-bloc in 1% uranyl acetate in 10%
ethanol for 1 h, dehydrated in ethanol and embedded in Epon. Sections were stained with
uranyl acetate and lead citrate and examined in a JEM-1400 Transmission Electron
Microscope (Jeol) equipped with TEM CCD camera (Olympus Soft Imaging Solutions
GmbH, Münster, Germany) (Study I).
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4.7 Immunofluorescence microscopy
4.7.1 Immunofluorescence microscopy of kidney tissue
     Rat kidney cryosections were fixed with PFA (followed by permeabilization with Triton
X-100) or acetone, washed with PBS, blocked with CAS-BLOCK (Invitrogen) and incubated
with primary antibodies diluted in ChemMate™ (DakoCytomation, Glostrup, Denmark) at
4°C overnight. The following day, sections were washed with PBS, incubated with
AlexaFluor secondary antibodies (Molecular Probes) and Hoechst 33342 (Sigma-Aldrich) for
nuclear staining. Sections were washed with PBS, mounted with Mowiol and examined with
a Zeiss Axioplan2 microscope (Carl Zeiss Microscopy) (Studies I and II).
4.7.2 Immunofluorescence microscopy of cultured cells
     Cells on glass coverslips were fixed with PFA, followed by permeabilization with Triton
X-100. After washing with PBS, cells were blocked in 2% FCS, 2% bovine serum albumin,
0.2%  fish  skin  gelatin  or  CAS-BLOCK  and  incubated  with  primary  antibodies  at  room
temperature for 1 h. After washing with PBS, cells were incubated with AlexaFluor
secondary antibodies. Actin stress fibers were visualized with TRITC-phalloidin (Molecular
Probes)  and  nuclei  with  Hoechst  33342 (Sigma-Aldrich).  Cells  were  washed  with  PBS and
mounted in Mowiol. Samples were examined with a Zeiss Axioplan2 microscope (Carl Zeiss
Microscopy), a Leica SP2 confocal microscope (Leica Microsystems, Wetzlar, Germany) or
with a Leica SP8 confocal microscope (Leica Microsystems) (Studies I-III).
4.7.3 Surface staining
     Mouse podocytes stably expressing nephrin were grown on coverslips. Cells were
incubated on ice for 15 min with primary antibody diluted in ice-cold PBS and 5% FBS.
After washes with PBS, cells were fixed with PFA, washed with PBS and blocked with 5%
FBS, followed by incubation with AlexaFluor secondary antibody (Molecular Probes). Cells
were  washed  with  PBS  and  mounted  in  Mowiol.  Samples  were  examined  with  a  Zeiss
Axioplan2 microscope (Carl Zeiss Microscopy) (Study III).
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4.8 Immunohistochemistry
     Human and mouse kidney samples were fixed with 10% formalin, dehydrated, and
embedded in paraffin. Immunoperoxidase staining was performed with a VectaStain Elite kit
(Vector Laboratories, Burlingame, CA, USA). Sections were deparaffinized, antigen retrieval
was performed by boiling for 15 min in a microwave oven in 10 mM citric acid, pH 6.0
(Studies I-III) or in 10 mM Tris, 1 mM EDTA and 0.05% Tween 20, pH 9.0 (Study III), and
endogenous peroxidase was inactivated by incubation in hydrogen peroxide in methanol for
30 min. Sections were blocked with CAS-block (Invitrogen) and incubated with primary
antibodies diluted in ChemMate™ (DakoCytomation) and with biotinylated secondary
antibodies followed by incubation with ABC-reagent and AEC (Sigma-Aldrich) for colour
development. Sections were counterstained with hematoxylin, mounted with Shandon Immu-
Mount (Thermo Scientific, Waltham, MA, USA) and examined by light microscope (Studies
I-III).
4.9 Statistical analysis
    In all experiments, the differences between the groups were evaluated with Student's t-test.
P-values less than 0.05 were considered statistically significant. Sex frequencies were
compared between cases and controls with the χ2 test. Normalized intensities of matched
spots were compared between the groups, and spots with intensity changes >1.5-fold with a
CI >95% were considered differentially expressed and significant. Results are presented as
means and STDEV. Analyses were performed using Excel (Microsoft, Redmond, WA, USA)
or SPSS PASW Statistics (version 18) software (IBM, Armonk, NY, USA) (Studies I-III).
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5 RESULTS
5.1 Ezrin is downregulated in diabetic kidney glomeruli and regulates actin
reorganization and glucose uptake in cultured podocytes (Study I)
5.1.1 Streptozotocin-induced diabetes leads to differential expression of glomerular
proteins
    To identify differentially expressed proteins that could be associated with the development
of diabetic kidney injury at an early stage, quantitative proteomic profiling of glomeruli
isolated from rats with streptozotocin-induced diabetes and controls was performed using 2D-
DIGE coupled with mass spectrometry. Analysis was performed 4 weeks after induction of
diabetes. The streptozotocin-injected rats used for the analysis were albuminuric and had high
blood  glucose  compared  to  controls  (Study  I,  Figure  1A  and  B),  but  did  not  yet  show
ultrastructural changes in glomeruli (Study I, Figure 1C and D). DeCyder software analysis
revealed 2274 spots, out of which 29 exhibited statistically significant differences (Student’s
t-test value ≤0.05) (Study I, Supplemental Figure S1; Study I, Supplemental Table S1). Mass
spectrometry identified a single protein in 12 of these spots, including several actin binding
and actin cytoskeleton organizing proteins. Among these were cytoskeletal linkers ezrin and
NHERF2, which were downregulated in the diabetic rat glomeruli. Organization of the actin
cytoskeleton in podocytes is altered in several types of glomerular diseases (Mathieson,
2012), but the regulation of actin dynamics in podocytes in diabetic nephropathy is not well
characterized. We therefore chose ezrin and NHERF2 for further analysis.
     Ezrin and NHERF2 showed a 2.1-fold and 1.94-fold decrease, respectively, in diabetic
glomeruli (Study I, Figure 1E-H; Study I, Supplemental Table S1). Quantitative Western
blotting confirmed that ezrin and NHERF2 were downregulated by 49% and 42%,
respectively, in the glomeruli of the streptozotocin-induced diabetic rats compared with
citrate-treated rat glomeruli (Study I, Figure 2A and B). We also observed that ezrin
expression was downregulated in mouse podocytes cultured in high glucose media (25 mM)
for two weeks (Wasik et al., unpublished data, Figure 8). Phosphorylation of ezrin (p-ezrin) at
threonine 567 was also reduced by 49% (Study I, Figure 2A and B). Immunostaining
revealed decreased expression of ezrin, NHERF2, and p-ezrin in the glomeruli of diabetic rats
confirming the data obtained by quantitative immunoblotting (Study I, Figure 2C-E and G-I).
Podocalyxin, which is linked to ezrin and the actin cytoskeleton via NHERF2 (Orlando et al.,
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2001), was also downregulated by 35% in the glomeruli of streptozotocin-treated rats (Study
I, Figure 2A and B). The expression of podocin remained unchanged (Study I, Figure 2A, B,
F and J). Immunostaining further confirmed the 2D-DIGE and quantitative Western blotting
results.
Figure 8. High glucose leads to downregulation of ezrin in mouse podocytes. (A) Ezrin is
downregulated by 34% in mouse podocytes cultured in high glucose media for two weeks.
Tubulin is included as a loading control. (B) Quantification of the ezrin level in (A). Mouse
podocytes were grown in high glucose media (25 mM) for two weeks. Cell lysates were
separated by SDS-PAGE and immunoblotted with anti-ezrin and anti-tubulin IgGs. Bars
show the mean and error bars the SD of three independent experiments. Statistical analysis
was carried out with Student’s t-test.
5.1.2 Knockdown of ezrin induces dynamic remodelling of the actin cytoskeleton in
podocytes
To study the role of ezrin in regulating podocyte function, we used siRNA-mediated
knockdown of ezrin in cultured mouse podocytes (Study I, Figure 3). Transfection of
podocytes with ezrin siRNA reduced the expression level of ezrin by 60% compared to the
control  siRNA-transfected  cells  (Study  I,  Figure  3A  and  B).  Another  member  of  the  ERM
family, moesin, was not affected by ezrin knockdown (Study I, Figure 3A and B).
As normal structure and function of podocytes are maintained by dynamic actin
cytoskeleton and ezrin is an important modulator of F-actin (Arpin et al., 1994; Vaheri et al.,
1997), we analyzed the effect of ezrin depletion on actin cytoskeleton organization in
podocytes. In control siRNA-treated cells, ezrin was expressed in the cytoplasm (Study I,
Figure 3C) while phalloidin, which visualizes filamentous actin, showed prominent actin
stress fibers (Study I, Figure 3D). Knockdown of ezrin by siRNA (Study I, Figure 3E) led to
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reduction of actin stress fibers and accumulation of actin in the cortical region of podocytes
(Study I, Figure 3F).
     Next, we searched for the mechanisms by which ezrin mediates actin remodelling. A
previous study showed that phosphorylated ERM-proteins co-distribute with cofilin-1 and F-
actin (Marsick et al., 2012). Cofilin-1 modulates actin dynamics via depolymerizing and
severing actin filaments (Nishida et al., 1984; Yonezawa et al., 1985; Theriot, 1997) and
cofilin-1 is an important regulator of actin cytoskeleton organization also in podocytes (Garg
et al., 2010; Ashworth et al., 2010). We therefore investigated the localization of cofilin-1
and phosphorylated, inactive cofilin-1 (p-cofilin-1) in ezrin depleted and control podocytes.
We found that cofilin-1 and phosphorylated cofilin-1 localize in the cytoplasm in control
siRNA-transfected podocytes (Study I, Figure 3G and H), whereas both proteins were
partially translocated to the cell periphery in ezrin-depleted podocytes (Study I, Figure 3I and
J). This suggests that ezrin loss induces partial relocalization of cofilin-1 to the plasma
membrane to mediate remodelling of the cortical actin cytoskeleton.
5.1.3 Knockdown of ezrin increases glucose uptake of podocytes and GLUT1
translocation to the plasma membrane
Dynamic remodelling of the actin cytoskeleton has been implicated in the translocation
and fusion of the GSVs with the plasma membrane and thus, in insulin-mediated glucose
uptake (Tong et al., 2001). An active role of cortical actin in this process has been proposed
previously (Omata et al., 2000). Ezrin increases the dynamic reorganization of the actin
cytoskeleton (Study I, Figure 3) and functions in the release of insulin granules by regulating
exocytosis in β-cells (Lopez et al., 2010). This suggests that ezrin could regulate the
trafficking of glucose transporters and glucose uptake in podocytes. To study this, we
measured 2-deoxy-D-glucose uptake in mouse podocytes transfected with ezrin siRNA. We
found that under basal conditions and in serum-starved podocytes, glucose uptake was
increased in ezrin-depleted podocytes by 53% and 31%, respectively, compared to control
siRNA-transfected cells (Study I, Figure 5A and B). Insulin stimulation increased glucose
uptake by 110% in control siRNA-transfected podocytes (Study I, Figure 5B). However, in
ezrin siRNA-transfected podocytes insulin increased glucose uptake only by 76% compared
to serum-starved, control siRNA-transfected cells (Study I, Figure 5B). These results indicate
that loss of ezrin in podocytes increases glucose uptake, but insulin-stimulated glucose uptake
is significantly inhibited by knockdown of ezrin.
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     We further investigated whether ezrin depletion would affect the trafficking of glucose
transporters, GLUT1 and GLUT4, in podocytes. Introduction of ezrin siRNA into mouse
podocytes induced translocation of GLUT1 to the plasma membrane under basal, starved and
insulin-stimulated conditions (Study I, Figure 8A, B, E, F, I and J). GLUT4 remained in the
cytoplasm of ezrin-depleted podocytes in basal and starved conditions (Study I, Figure 8C, D,
G and H), but translocated to the plasma membrane after insulin stimulation (Study I, Figure
8K and L). This suggests that depletion of ezrin increases glucose uptake by enhancing
translocation of GLUT1 to the plasma membrane.
5.1.4 Cofilin-1 is involved in ezrin-mediated cortical actin remodelling
     As cofilin-1-mediated actin reorganization is involved in the translocation of GSVs to the
cell surface in muscle cells (Chiu et al., 2010) and knockdown of ezrin induces dynamic
remodelling of the actin cytoskeleton in podocytes, we analyzed both actin organization and
cofilin-1/p-cofilin-1 localization in control and ezrin-depleted podocytes stimulated with
insulin. In control siRNA-transfected podocytes insulin stimulation induced actin remodelling
and increased cortical actin (Study I, Figure 6A and B). In starved, ezrin-depleted podocytes
cortical actin was present (Study I, Figure 6C), but insulin stimulation reduced the cortical
actin and increased stress fibers (Study I, Figure 6D). These data indicate that insulin
stimulation increases cortical actin reorganization in control podocytes, and that ezrin
depletion reduces insulin-induced cortical actin remodelling.
     We also found that localization of cofilin-1 and p-cofilin-1 reflects the dynamic changes
observed in the organization of the actin cytoskeleton upon ezrin knockdown and insulin
stimulation. In control siRNA-transfected podocytes, insulin induced partial translocation of
cofilin-1 and p-cofilin-1 from their cytoplasmic location (Study I, Figure 6E and I) to the cell
periphery  (Study  I,  Figure  6F  and  J).  Introduction  of  ezrin  siRNA  into  serum-starved
podocytes resulted in cofilin-1 and p-cofilin-1 partial translocation to the periphery of
podocytes (Study I, Figure 6G and K), but after insulin stimulation of ezrin-depleted
podocytes, both proteins were found only in the cytoplasm (Study I, Figure 6H and L). The
data suggest that cofilin-1 is involved in ezrin-mediated remodelling of cortical actin.
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5.1.5 Phosphorylation of cofilin-1 is regulated by insulin in cultured podocytes and
increases in glomeruli of diabetic rats
     A previous study showed that short-term treatment of muscle cells with insulin leads to
dephosphorylation of cofilin-1 (Chiu et al., 2010). Similarly, a reduced level of inactive,
phosphorylated cofilin-1 was observed in podocytes stimulated with insulin for 15 minutes
(Study I, Figure 7A-C). However, culturing podocytes in the presence of insulin for 48 hours
increased the level of phosphorylated cofilin-1 (Study I, Figure 7D-F). The effect of insulin
on the activity of cofilin-1 is thus determined by the acute or chronic nature of the exposure,
either activating or inactivating it, respectively.
Furthermore, we speculated that the level of phosphorylated cofilin is altered in glomeruli
of streptozotocin-treated rats. Quantitative Western blotting indicated that the level of total
cofilin-1 remained unchanged, but phosphorylated cofilin-1 was increased in the glomeruli of
the diabetic rats (Study I, Figure 9). This suggests that cofilin-1 is inactivated
(phosphorylated) in glomeruli in experimental diabetes.
5.1.6 Expression of ezrin is reduced in glomeruli of obese Zucker rats and in
glomeruli of human patients with Type 2 diabetes
     Obese Zucker rats and their age-matched lean controls were used to investigate the
expression level of ezrin. Quantitative Western blotting revealed that ezrin expression is
decreased by 20% in the glomeruli of obese Zucker rats when compared to lean Zucker rats
(Study I, Supplemental Figure S2).
     The expression of ezrin was also studied in human kidney biopsy specimens obtained
from patients with T2DM and controls. Interestingly, immunohistochemistry revealed
significantly  lower  expression  of  ezrin  in  the  glomeruli  of  patients  with  diabetes  (Study  I,
Figure 10).
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5.2 Septin 7 and nonmuscle myosin IIA regulate glucose uptake into podocytes and
compete for binding to the target membrane SNARE complex (Studies II and III)
5.2.1 Septin 7 is a novel interaction partner of CD2AP, nephrin and nonmuscle
myosin IIA
 As  the  adaptor  protein  CD2AP  is  essential  for  glomerular  ultrafiltration  (Shih  et  al.,
1999), we searched for novel interaction partners of CD2AP. A pull-down assay of
glomerular lysates with the GST-3.SH3 domain of CD2AP followed by mass spectrometry
identified the small cytoskeletal GTPase septin 7 as a novel interaction partner of CD2AP
(Study II, Figure 1A). Septin 7 was originally discovered in yeast (Hartwell, 1997) and
shown to be involved in cell division, polarity, and vesicle trafficking (Hsu et al., 1998;
Beites et al., 1999; Kinoshita et al., 2002; Kremer et al., 2007). To analyze which domain(s)
of CD2AP are required for the interaction with septin 7, we performed experiments to pull
down  endogenous  septin  7  with  the  different  SH3  domains  of  CD2AP  and  with  GST  as  a
negative control. The pull-downs, resolved by SDS-PAGE and immunoblotted with septin 7
antibody, showed that 2.SH3 and 3.SH3 domains of CD2AP bind to septin 7 (Study II, Figure
1B). Pull-down assays with different domains of septin 7 fused to GST were also performed.
The COOH-terminus of septin 7 was found to be involved in the binding to CD2AP (Study
II, Figure 1D). To confirm the physiological interaction between septin 7 and CD2AP, a co-
immunoprecipitation was performed, showing that two different CD2AP antibodies co-
immunoprecipitate septin 7 from HEK293 cells (Study II, Figure 1E). Furthermore, double
staining with septin 7 and CD2AP in rat kidney sections revealed partial colocalization of the
proteins, supporting their interation (Study II, Figure 2D-F).
     Mammalian septins have been shown to form homo-oligomers in vitro and hetero-
oligomeric polymers in vitro and in vivo (Joberty et al., 2001; Nagata et al., 2004). Using an
immunoprecipitation  approach,  we  found  that  septin  7  forms  a  complex  with  septin  9  and
septin 11 in differentiated cultured human podocytes (Study II, Supplemental Figure S3A-C)
We further found that depletion of septin 7 reduces the expression of the other members of
the complex in human podocytes (Study II, Supplemental Figure S3D and E) and in HIRc
cells (Study II, Supplemental Figure S4A and B).
     In order to characterize the function of septin 7 in podocytes, we searched for its
interaction partners. Co-immunoprecipitation analysis of human podocytes with septin 7
antibody, followed by mass spectrometry, identified NMHC-IIA as a novel interaction
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partner  of  septin  7  (Study  III,  Figure  1A).  NM-II  is  a  major  component  of  the  actomyosin
cytoskeleton (reviewed in Sellers, 2000). In human cells, three NMHCs (IIA, IIB, and IIC)
are encoded by distinct genes (MYH9, MYH10, and MYH14, respectively) and constitute the
NM-II isoforms, which are named NMHC-IIA, NMHC-IIB, and NMHC-IIC, respectively
(Conti and Adelstein, 2008; Vicente-Manzanares et al., 2009). NM-IIs are ubiquitously
expressed but differ with respect to their localization and expression level in the cells (Conti
and Adelstein, 2008). NMHC-IIA is widely expressed in the kidney, mainly in glomerulus
and peritubular vessels (Arrondel et al., 2002), whereas NMHC-IIB localizes in mesangial
cells (Johnstone et al., 2011). NM-II is comprised of two heavy chains (MHCs) and two pairs
of light chains: essential light chains (ELCs) and regulatory light chains (RLCs) (reviewed in
Sellers, 2000). NM-IIA is activated and regulated by the reversible phosphorylation of the
MHC (p-MHC) on its serine 1943 residue (S1943) and RLC (pp-RLC) on its threonine 18
(T18) and serine 19 (S19) residues (Scholey et al., 1980; Sellers et al., 1981). The physical
interaction of septin 7 and NMHC-IIA was confirmed using co-immunoprecipitation and
Western blotting in cultured human and mouse podocytes, and in rat glomeruli (Study III,
Figure 1B). Further, we produced by retroviral infection mouse podocytes stably expressing
nephrin (Study III, Figure 2A and B), and found that both septin 7 (Study II, Figure 1F-H)
and NMHC-IIA (Study III, Figure 2H) bind to nephrin in rat glomeruli and nephrin-
expressing mouse podocytes, respectively.
     Expression of septin 7, CD2AP, and NMHC-IIA was confirmed by Western blotting in
proliferating and differentiated cultured human podocytes (Study II, Figure 2B; Study III,
Figure 1C). We also analyzed the localization of septin 7 and NMHC-IIA in cultured human
podocytes. Septin 7 appears as filaments in proliferating and differentiated podocytes (Study
II, Figure 2H and I). In proliferating podocytes, septin 7 also localizes in the midbodies
(Study II, Figure 2G). We also investigated septin 7 localization in subcellular fractions of
mouse podocytes and found that septin 7 is present in both the membrane and cytosolic
fractions (Study II, Supplemental Figure S6A-C). NMHC-IIA shows a cytoplasmic
filamentous pattern in human podocytes (Study III, Figure 1E).
     To  confirm  the  expression  of  septin  7  and  NMHC-IIA  in  glomeruli,  rat  glomerular  and
tubular lysates were isolated by the sieving technique and immunoblotted with septin 7 and
NMHC-IIA antibodies, showing that septin 7 and NMHC-IIA are expressed in both
glomeruli  and  tubuli  in  the  kidney  (Study  II,  Figure  2A;  Study  III,  Figure  1D).  To  more
precisely localize septin 7, NMHC-IIA, p-MHC, and pp-RLC in glomeruli,
immunopreroxidase staining of mouse and human kidney sections was performed. Septin 7,
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NMHC-IIA,  p-MHC  and  pp-RLC  were  shown  to  be  expressed  in  podocytes  (Wasik  et  al.,
unpublished data, Figure 9; Study II, Figure 2C; Study III, Figure 1F).
Figure 9. Septin 7, NMHC-IIA, phosphorylated MHC and phosphorylated RLC are
expressed in human glomeruli, where they localize in podocytes. Human kidney samples
were fixed with formaldehyde and embedded in paraffin. Deparaffinized sections were
stained with anti-septin 7 (A), anti-NMHC-IIA (B), anti-phosphorylated MHC (p-MHC) (C)
and anti-phosphorylated RLC (pp-RLC) (D) IgGs. VectaStain Elite ABC kit (Vector
Laboratories) and AEC (DakoCytomation) were used for detection. Hematoxylin-
counterstained slides were photographed using Nikon Eclipse 800 microscope. Higher
magnifications of the boxed regions are shown in the insets. Scale bar, 50 µm.
5.2.2 Localization of septin 7 depends on CD2AP and intact actin cytoskeleton
     In cultured mouse podocytes, septin 7 was shown to be expressed in a filamentous pattern
along actin stress fibers (Wasik et al., modified Figure 10A-D and I-L; Study II,
Supplemental Figure S1A-D and I-L). When actin organization was disrupted with
cytochalasin D, the majority of septin 7 localized in rings formed by rolling up of linear
septin 7 filaments (Wasik et al., modified Figure 10E-H and M-P; Study II, Supplemental
Figures S1E-H and M-P). These rapid changes in localization reveal that septin 7
organization in podocytes is dynamic and depends on an intact actin cytoskeleton.
     We also analysed whether septin 7 localization depends on CD2AP. In wild-type mouse
podocytes, septin 7 is expressed as short filaments (Study II, Figure 3A-D), whereas in
CD2AP -/- podocytes, septin 7 filaments are lost (Study II, Figure 3E-H) indicating that loss
of CD2AP is associated with the disappearance of actin stress fibers and septin 7 filaments.
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Figure 10. Localization of septin 7 depends on an intact actin cytoskeleton. Double
labeling of proliferating (A-H) and differentiated (I-P) human podocytes for septin 7 (green)
and actin (red). Nuclei are visualized with Hoechst (blue). In proliferating and differentiated
human podocytes, septin 7 appears as filaments which occasionally co-localize with actin
stress fibers (A-D, I-L). In podocytes treated with cytochalasin D, septin 7 curled and
localized in rings (arrows) (E-H, M-P). Cultured human podocytes were treated or not with 5
µM cytochalasin D, fixed with PFA, labeled with septin 7 IgG and phalloidin, and examined
by fluorescence microscopy. Scale bar, 20 µm; in D, H, L, P, 7 µM (Modified from Study II,
Supplemental Figure S1).
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5.2.3 Depletion of septin 7 and nonmuscle myosin IIA affect glucose uptake in
cultured podocytes
     Septins are known to be involved in exocytosis in nondividing neurons (Hsu et al., 1998;
Beites et al., 1999). As podocytes are terminally differentiated cells, we hypothesised that
septin 7 may affect exocytosis in these cells. Our hypothesis was supported by the fact that
septin 7 interacts with nephrin (Study II, Figure 1F-H), a protein that is known to be involved
in GSV fusion with the plasma membrane (Coward et al., 2007). Indeed, knockdown of
septin 7 by siRNA in HIRc cells increased 2-deoxy-D-glucose uptake under basal, starved,
and insulin-stimulated conditions compared to the control siRNA-treated cells (Study II,
Figure 4A-C). Alteration of septin 7 assembly and dynamics by forchlorfenuron (FCF) (Hu et
al., 2008) caused a similar effect as septin knockdown by siRNA in both HIRc cells (Study II,
Figure 4D and E) and mouse podocytes (Study II, Figure 4F and G). FCF also changed septin
7 organization to bundle-like filaments that accumulate at the cell periphery, without
affecting the actin cytoskeleton (Study II, Supplemental Figure S5).
     We also measured glucose uptake in mouse podocytes overexpressing septin 7 (Study III,
Supplemental Figure S1) and found that glucose uptake was decreased by 20% in septin 7-
overexpressing podocytes compared to empty vector-transfected cells under basal conditions
(Study III, Supplemental Figure S1F). In serum-starved podocytes, overexpression of septin 7
did not affect glucose uptake compared to serum-starved, empty vector-transfected cells
(Study III, Supplemental Figure S1G). In insulin-stimulated septin 7-overexpressing
podocytes, glucose uptake remained unchanged compared to serum-starved, empty vector-
transfected cells (Study III, Supplemental Figure S1G). In contrast, in control podocytes
insulin increased glucose uptake (Study III, Supplemental Figure S1G). This confirmed our
previous data showing that septin 7 is a negative regulator of glucose uptake into podocytes.
    We also further investigated the role of NMHC-IIA in the regulation of GSV trafficking in
podocytes and found that siRNA-mediated depletion of NMHC-IIA in mouse podocytes
(Study III, Figure 2C and D) decreased insulin-stimulated glucose uptake (Study III, Figure
2F) without affecting glucose uptake at basal (Study III, Figure 2E) and starved states (Study
III, Figure 2F). This indicates that septin 7 and NMHC-IIA have opposite effects on glucose
uptake into podocytes.
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5.2.4 Septin 7 and nonmuscle myosin IIA interact with proteins involved in GSV
trafficking
     To search for the mechanism by which septin 7 regulates glucose uptake, we first
determined if septin 7 regulates the insulin-activated PI3K signaling pathway.
Phosphorylation of AKT was examined in septin 7 depleted and control siRNA-treated HIRc
cells. The results indicate that depletion of septin 7 has no effect on the total level of AKT or
on the insulin-stimulated phosphorylation of AKT, indicating that loss of septin 7 does not
affect insulin signal transduction (Study II, Figure 5A-D). Previous studies have also shown
that myosin IIA depletion does not inhibit insulin signal transduction (Chung et al., 2010).
     To determine if septin 7 and NMHC-IIA could be involved in GSV trafficking, we
investigated their interaction with the proteins involved in the process. GSV trafficking
consists  of  several  steps.  The  SNAREs  complex,  including  v-SNARE,  VAMP2,  and  t-
SNAREs, such as syntaxin 4 and SNAP23, function in the docking and fusion steps of GSVs
with the plasma membrane (Foster and Klip, 2000; reviewed in Sollner, 2003; Watson et al.,
2004). Co-immunoprecipitation with septin 7 antibodies revealed that septin 7 interacts with
VAMP2 in HIRc cells and the interaction is not dependent on insulin stimulation (Study II,
Figure 5E and F). We also found that NMHC-IIA forms a complex with SNAP23 in mouse
podocytes (Study III,  Figure 2G) and that septin 7 is  also a part  of this complex (Study III,
Figure 2H).
5.2.5 Phosphorylated myosin RLC competes with septin 7 for binding to the SNARE
complex
     Septin 7 and NMHC-IIA have opposite effects on glucose uptake into podocytes and both
interact with the t-SNARE protein, SNAP23. Accordingly, we hypothesized that septin 7 and
NMHC-IIA compete for binding to SNAP23 (Figure 11A). Indeed, co-immunoprecipitation
and Duolink proximity ligation assay (PLA) studies on NMHC-IIA-depleted and control
siRNA-treated mouse podocytes revealed increased complex formation between septin 7 and
SNAP23 in NMHC-IIA-depleted podocytes (Figure 11B; Study III, Figure 3A-E).
    We further knocked down septin 7 to investigate the effect of septin 7 loss on binding of
NMHC-IIA, p-MHC, and pp-RLC to SNAP23. Although loss of septin 7 decreased the
interaction of SNAP23 with NMHC-IIA (Study III,  Figure 4A and B) and SNAP23 with p-
MHC (Study III, Figure 4A and C), it increased complex formation between SNAP23 and pp-
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RLC (Figure 11C; Study III, Figure 4A and D). The interactions were further confirmed by
Duolink proximity ligation assay (Study III, Figure 4E-M).
     To further confirm that septin 7 and pp-RLC compete for binding to SNAP23, we
overexpressed septin 7. Increased expression of septin 7 facilitated complex formation of
SNAP23 with NMHC-IIA (Study III, Supplemental Figure S2A and B) and SNAP23 with p-
MHC (Study III, Supplemental Figure S2A and C), and, as expected, decreased the
interaction  of  SNAP23  with  pp-RLC  (Study  III,  Supplemental  Figure  S2A  and  D).  The
interactions were confirmed by Duolink proximity ligation assays (Study III, Supplemental
Figure S2E-M), which confirmed our hypothesis that septin 7 competes with pp-RLC for
binding to SNAP23.
5.2.6 Insulin  regulates  the  association  of  septin  7  and  phosphorylated  myosin  RLC
with SNAP23
     As knockdown of NMHC-IIA reduced insulin-induced glucose uptake and septin 7 and
pp-RLC competed for binding to SNAP23, we speculated that insulin may regulate the
association between septin 7, pp-RLC and SNAP23. Using co-immunoprecipitation and
Duolink proximity ligation assays, with and without insulin stimulation, we found that insulin
stimulation reduces the association of septin 7 with SNAP23 (Study III, Figure 5A, B, D, E
and I), but does not change the interaction of septin 7 with syntaxin 4 (Study III, Figure 5A
and C). In line with this, insulin increases complex formation between pp-RLC and SNAP23
(Study III, Figure F, G and J). These data provide mechanistic insight to the regulatory role of
insulin in glucose uptake in podocytes by affecting SNAP23 complex formation with septin 7
and pp-RLC (Figure 11B and C).
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Figure 11. Schematic illustration of how septin 7 and phosphorylated myosin RLC
compete for binding to SNAP23. (A) Both septin 7 and nonmuscle myosin IIA form a
complex with SNAP23 in the basal state. (B) NMHC-IIA knockdown (NMHC-IIA KD)
increases the interaction between septin 7 and SNAP23. (C) Loss of septin 7 (septin 7 KD)
increases the interaction between phosphorylated myosin RLC and SNAP23.
5.2.7 Septin 7 and NMHC-IIA affect SNARE complex formation
     The fact that septin 7 associates with both v-SNARE VAMP2 (Study II, Figure 5E and F)
and t-SNARE SNAP23 (Study III, Figure 2H), as well as with nephrin (Study II, Figure 1F-
H) led us to speculate that septin 7 forms a filamentous barrier between the GSVs and the
plasma membrane. Previous studies have shown that GSV fusion with the plasma membrane
is facilitated by the interaction of nephrin with VAMP2 (Coward et al., 2007). Accordingly,
we investigated the association of nephrin and VAMP2 in septin 7-depleted HIRc cells which
overexpress nephrin. Septin 7 knockdown increased the interaction between nephrin and
VAMP2 (Study II, Figure 6B and C) and also between syntaxin 4 and VAMP2 (Study II,
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Figure 6B and D), supporting the view that septin 7 forms a filamentous barrier between the
GSVs and the plasma membrane.
     Our data suggest that depletion of NMHC-IIA affects complex formation between v-
SNAREs and t-SNARES. Indeed, we observed that siRNA-mediated knockdown of NMHC-
IIA reduces the interaction of VAMP2 with SNAP23 (Study III,  Figure 6A-E),  whereas the
interaction between VAMP2 and syntaxin 4 is not affected (Study III, data not shown). This
suggests that knockdown of NMHC-IIA inhibits the association between the two key
components of the SNARE complex, VAMP2 and SNAP23, and therefore reduces the final
steps of GSV trafficking and fusion with the plasma membrane in podocytes, which leads to
reduced glucose uptake.
5.2.8 Phosphorylated myosin RLC is upregulated in glomeruli in diabetic rats and in
cultured human podocytes exposed to sera from Type 1 diabetic patients with
macroalbuminuria
     The expression of NMHC-IIA, p-MHC, and pp-RLC was studied in the glomeruli of 40-
week old obese Zucker rats and age-matched lean controls. Obese Zucker rats are insulin
resistant and slightly diabetic due to a mutation in the leptin receptor gene, and develop
albuminuria by 40 weeks of age (Chua et al., 1996). Quantitative Western blotting revealed
that NMHC-IIA and p-MHC were downregulated in the glomeruli of obese Zucker rats when
compared  to  lean  controls  (Study  III,  Figure  7A-C),  whereas  pp-RLC  was  significantly
upregulated in the glomeruli of obese rats (Study III, Figure 7A and D).
     The expression of septin 7, NMHC-IIA, p-MHC, and pp-RLC was also studied by
immunohistochemistry in human kidney samples obtained from patients with T2DM and
from  controls.  The  patients  with  T2DM  did  not  have  clinical  nephropathy,  and
histopathological  analysis  revealed  no  diagnostic  signs  of  DN.  The  expression  of  septin  7,
NMHC-IIA and p-MHC did not differ between the groups, however, pp-RLC showed
significantly higher expression in the glomeruli of patients with diabetes (Study III, 7E-G).
We next investigated the expression levels of septin 7, NMHC-IIA, p-MHC, and pp-RLC
in human podocytes treated with sera of T1DM patients with normo- and macroalbuminuria.
The expression of p-MHC, NMHC-IIA, and septin 7 did not differ between the groups (Study
III, Figure 8A-D). Interestingly, the pp-RLC level was increased by 75% in human podocytes
treated with sera from macroalbuminuric patients compared to normoalbuminuric controls
(Study III, Figure 8A and E).
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6 DISCUSSION
6.1 Diabetes-induced changes in the protein expression profile of glomeruli isolated
from rats with streptozotocin-induced diabetes
     To identify differentially expressed proteins that could be associated with the development
of podocyte injury in diabetes, we performed quantitative proteomic profiling of glomeruli
isolated from rats with streptozotocin-induced diabetes and controls. Major changes were
observed in actin-binding proteins, including ezrin and NHERF2, apoptosis-associated
proteins, regulators of oxidative tolerance, and DNA binding and repair proteins (Study I,
Supplemental Table S1). The actin cytoskeleton integrity in podocytes is altered in several
types  of  glomerular  diseases.  This  raises  great  interest  in  proteins  that  function  in  the
regulation of dynamic actin organization as potential therapeutic targets in the treatment of
glomerular diseases, including DN. Consequently, we chose ezrin for further analysis. In
podocytes, ezrin and its interaction partner, NHERF2, are important regulators of podocyte
function as they link podocalyxin, the major sialoprotein of podocytes, to the actin
cytoskeleton (Takeda et al., 2001). However, the exact role of ezrin protein complex in
podocyte injury in DN has not been studied before.
6.2 Role of ezrin in the regulation of actin reorganization and glucose uptake in
cultured podocytes
     To fulfill its biological function, ezrin needs to be activated via phosphorylation on its
threonine 567 residue (Fievet et al., 2004). We found that in glomeruli of streptozotocin-
treated rats, the levels of both total and phosphorylated ezrin were reduced. We also found
that the expression of ezrin is downregulated in glomeruli of obese Zucker rats and in
podocytes of human patients with T2DM without clinical nephropathy or histopathological
diagnostic signs of DN. Supporting our findings, phosphorylation of ezrin has been reported
to  be  reduced  in  the  skeletal  muscle  of  obese  patients  with  T2DM  (Chun  et  al.,  2011).
Previously, reduction of ezrin was suggested as a marker for evaluating the prognosis of
nephrotic syndrome in children (Ostalska-Nowicka et al., 2006). Our data indicate that
downregulation of ezrin and/or its activity may be involved in the development of diabetic
complications.
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     We further observed that depletion of ezrin induces dynamic remodelling of cortical actin
in cultured podocytes under basal conditions, but diminishes the insulin-induced dynamics of
cortical actin. In muscle cells, remodelling of cortical filamentous actin is required for
GLUT4 translocation (Tong et al., 2001). In podocytes, glucose uptake and GLUT4
translocation  also  depend on  the  actin  cytoskeleton  (Coward  et  al.,  2005).  Using  an  siRNA
approach, we found that depletion of ezrin in podocytes increased glucose uptake under basal
conditions. After insulin stimulation, glucose uptake was still enhanced but remained lower in
ezrin-depleted podocytes than in control siRNA-transfected podocytes. The increase in
glucose uptake in ezrin knockdown podocytes was due to enhanced trafficking of the
constitutive glucose transporter, GLUT1, to the plasma membrane. Despite reduced cortical
actin remodelling, we observed translocation of GLUT4 to the plasma membrane after insulin
stimulation in ezrin-depleted podocytes. However, this may be due to the fact that ezrin
depletion achieved by siRNA was only partial.
     Ezrin-dependent remodelling of actin involves the actin severing protein cofilin-1.
Phosphorylation of cofilin-1 on serine 3 leads to its inactivation resulting in reduced binding
to actin and depolymerizing activity (Moriyama et al., 1996; Heyworth et al., 1997). Cofilin-1
is essential for structural changes to the actin cytoskeleton during recovery from podocyte
injury, as cofilin-1 mutant podocytes fail to recover following injury (Garg et al., 2010).
Further, knockdown or mutation of cofilin-1 disturbs the filtration barrier in zebrafish
(Ashworth et al., 2010), and mice with podocyte-specific deletion of cofilin-1 develop
proteinuria (Garg et al., 2010). We observed phosphorylated cofilin-1 at the cell membrane of
cultured podocytes after insulin stimulation. This may appear controversial, as one would
expect the dynamic organization of cortical actin to require cofilin-1 in its active,
dephosphorylated form. However, a similar observation was previously made in human
epidermoid carcinoma KB cells, in which cofilin and p-cofilin were found at the plasma
membrane after insulin stimulation (Arai and Atomi, 2003). The authors speculated that
phosphorylated cofilin at the membrane could reflect a rapid
phosphorylation/dephosphorylation cycle of cofilin or it could represent the residual pool of
phosphorylated protein waiting to be dephosphorylated (Arai and Atomi, 2003).
     In cultured podocytes, phosphorylation of cofilin-1 depends on the length of insulin
stimulation.  Similar  to  muscle  cells  (Chiu  et  al.,  2010),  short-term  insulin  treatment  of
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podocytes induced cofilin-1 dephosphorylation. However, long-term insulin treatment
increased the level of phosphorylated cofilin-1. Inactivation of cofilin-1 by phosphorylation
may lead to disturbed actin remodelling and disturbances in podocyte function. Further,
cofilin-1 is phosphorylated in diabetic rat glomeruli and it was previously shown to be
phosphorylated in human patients with glomerular diseases affecting podocytes (Ashworth et
al.,  2010).  This  would  possibly  reduce  the  ability  of  podocytes  to  respond  to  changes  in
glomerular pressure. Surprisingly, in puromycin aminonucleoside-induced nephrotic
glomeruli,  phosphorylation  of  cofilin-1  was  shown  to  be  reduced  (Garg  et  al.,  2010).  This
may be due to differences between species and diseases or disease models, or the stage of
disease progression. They may also reflect constant recycling of cofilin-1 between its active
and inactive forms. Nevertheless, our data indicate an important role for ezrin and cofilin-1 in
maintaining the functional organization of the actin cytoskeleton in cultured podocytes.
6.3 Septin 7 and nonmuscle myosin IIA regulate glucose uptake into podocytes
					In cultured human podocytes, septin 7 forms a complex with CD2AP, an 80-kDa cy-
toplasmic adapter protein that was originally found as an interaction partner of the T-cell
adhesion molecule CD2 (Dustin et al., 1998) and shortly after was shown to be essential for
kidney ultrafiltration function (Shih et al., 1999). The C-terminus of septin 7 (aa 179-418),
which contains a coiled-coil domain and part of the GTP-binding domain, as well as the SH3
domains of CD2AP, participate in the formation of the complex. Septin 7 filaments partially
overlap with actin stress fibers in podocytes, suggesting that the association of septin 7 and
actin is mediated by other molecules. CD2AP may mediate binding of septin 7 to actin, as
CD2AP binds actin directly (Lehtonen et al., 2002) and the localization of CD2AP depends
on an intact actin architecture (Lehtonen et al., 2002). Septin 7 also associates with nephrin,
which has previously been shown to form a complex with CD2AP (Shih et al., 2001; Palmen
et al.,  2002).  Further,  we found that septin 7 localization depends on CD2AP, as CD2AP-/-
podocytes show loss of actin stress fibers (Yaddanapudi et al., 2011) and septin 7 filaments.
     Septins are evolutionarily conserved and contain a GTP-binding domain and variable NH2
and COOH termini (Kinoshita, 2003; Hall et al., 2005). To date, 13 septin genes have been
reported in mammals. Many of them undergo alternative splicing, which means that the
number of septin isoforms is even greater (Kinoshita, 2003; Hall et al., 2005). These GTP-
binding proteins have several roles in cell division, cytoskeletal organization, and vesicle
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trafficking (Hsu et al., 1998; Beites et al., 1999; Kinoshita et al., 2002; Kremer et al., 2007).
One factor that is crucial for their functions is the ordered assembly of individual septins into
homo- and heterooligomeric core complexes that form higher-order structures such as
filaments or rings (Joberty et al., 2001; Nagata et al., 2004). Septin 7 forms a complex with
septin 2, septin 6, septin 8, septin 9b, and septin 11 (Kinoshita, 2003; Nagata et al., 2004).
We found that septin 7 associates with septin 9 and septin 11 in podocytes. The fact that
septin 7 lacks the proline-rich domain (that binds SH3 domains) and its presence in septin 9
(Hall and Russell, 2004) suggest that the interaction between septin 7 and CD2AP could be
mediated by septin 9. 		
					Our data demonstrate that also NMHC-IIA interacts with septin 7. Previously found that
septin 2 binds directly to NM-IIA (Joo et al., 2007). NMHC-IIA is expressed in podocytes,
and has been suggested to function as a major component of the actin-myosin contractile
apparatus, helping podocytes to respond to changes in glomerular pressure and contributing
to foot process retraction (Arrondel et al., 2002). It may be that NMHC-IIA also participates
in mediating the interaction of septin 7 with the actin filaments.
     Septin 7 localizes in the midbody of proliferating podocytes, and therefore it apparently
participates in regulating cell division in podocytes. However, mature podocytes in vivo are
terminally differentiated and do not divide. Studies in post-mitotic neurons showed that
septins regulate exocytosis (Hsu et al., 1998; Beites et al., 1999; Vega and Hsu, 2003).
Furthermore, interaction of septin 7 with nephrin, a protein required for the fusion of the
GSVs with the plasma membrane in podocytes (Coward et al., 2007), suggested that septin 7
could function in vesicle trafficking in these cells. We therefore investigated the role of septin
7 in GSV exocytosis. We found that septin 7 ablation does not affect the insulin-stimulated
activation of the PI3K signaling pathway in podocytes, indicating that septin 7 rather
regulates the trafficking of GSV. Indeed, depletion of septin 7 increases glucose uptake under
basal conditions, but the increase is more pronounced after insulin stimulation, indicating that
septin 7 negatively regulates GSV trafficking. The data also suggest that septin 7 affects both
the constitutive glucose transporter GLUT1 and the insulin-stimulated glucose transporter
GLUT4. The trafficking of GSVs involves a SNARE complex that facilitates the docking and
fusion of GSVs with the plasma membrane (Foster and Klip, 2000; reviewed in Sollner,
2003; Watson et al., 2004). The SNARE complex includes a v-SNARE on GSVs, VAMP2,
and t-SNAREs on the plasma membrane, such as syntaxin 4 and SNAP23 (Rothman, 1994;
Weber et al., 1998). We found that septin 7 interacts with VAMP2 independently of insulin
stimulation. Septin 7 also binds to the plasma membrane proteins nephrin and SNAP23.
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Nephrin regulates glucose uptake in podocytes by interacting with VAMP2 and facilitates the
fusion of GSVs with the plasma membrane (Coward et al., 2007). Binding of septin 7 to both
vesicle and target SNAREs indicates that septin 7 forms a filamentous barrier and thereby
restricts movement of the vesicles to the plasma membrane. Indeed, depletion of septin 7
increases the interaction between nephrin and VAMP2, and also between syntaxin 4 and
VAMP2. Importantly, we found that insulin stimulation reduces the interaction between
septin 7 and SNAP23. This allows formation of the SNARE complex and further supports a
filametous barrier function of septin 7. The interaction of septin 7 with nephrin in glomeruli
suggests that the two proteins may function together in regulating GSV trafficking in
glomeruli in vivo.
          Opposite to the negative regulatory role of septin 7 in glucose uptake, NMHC-IIA
positively regulates insulin-stimulated glucose uptake into podocytes. The role of NMHC-IIA
in regulating glucose uptake is supported by our finding that that NMHC-IIA interacts with
SNAP23 and nephrin in podocytes. Previous studies in adipocytes have also shown also that
pharmacological inhibition of myosin II activity (Steimle et al., 2005; Fulcher et al., 2008) or
knockdown of myosin IIA (Chung et al., 2010) significantly reduced insulin-stimulated
glucose uptake by inhibiting GLUT4 incorporation into the plasma membrane and GLUT4
intrinsic activity, but not by impairing insulin signal transduction and GLUT4 translocation
(Chung et al., 2010).
     NM-IIA is activated by phosphorylation of its regulatory light chain (RLC) (Scholey et al.,
1980). The observation that septin 7 and NMHC-IIA have opposite effects on glucose uptake,
and the fact that septin 7 and pp-RLC compete for binding to SNAP23, provide a mechanistic
insight into how GSV trafficking in podocytes is regulated by septin 7 and NM-IIA,
indicating an important role for pp-RLC. Phosphorylation of the RLC by a specific myosin
light chain kinase (MLCK) has previously been shown to be essential for granule transport in
chromaffin cells (Neco et al., 2004) and insulin-stimulated GLUT4 translocation in
adipocytes (Choi et al., 2006; Fulcher et al., 2008). Insulin increases phosphorylation of the
RLC and inhibition of its phosphorylation subsequently blocks glucose transport (Choi et al.,
2006). We found that pp-RLC is upregulated in glomeruli of human patients with T2DM and
in obese Zucker rats, as well as in human podocytes exposed to sera of T1DM patients with
macroalbuminuria. This indicates that some factors in the macroalbuminuric sera activate
RLC and may thereby increase GSV trafficking and glucose uptake into podocytes. A
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previous study showed that septin 2-containing filaments act as a scaffold for NM-IIA and
ROCK and CRIK kinases to fully activate NM-IIA to ensure progression of cytokinesis (Joo
et al., 2007). Further studies are needed to define whether septin complexes scaffold NM-IIA
and MLCK to control GSV trafficking and glucose uptake in insulin sensitive cells.
     Depletion of NMHC-IIA inhibits v-SNARE/t-SNARE association in both podocytes (this
study) and adipocytes (Chung et al., 2010). In adipocytes, knockdown of NMHC-IIA inhibits
insulin-stimulated interaction between VAMP2 and syntaxin 4 (Chung et al., 2010). We did
not observe any difference in the complex formation between VAMP2 and syntaxin 4 in
podocytes under basal conditions, similarly as shown previously in adipocytes (Chung et al.,
2010). However, we found that loss of NMHC-IIA in podocytes inhibits the interaction
between VAMP2 and SNAP23. In addition, increased interaction of septin 7 and SNAP23
reduces the binding capacity of SNAP23 to VAMP2. Importantly, we found that insulin
stimulation reduces the interaction between septin 7 and SNAP23, and increases the
interaction between pp-RLC and SNAP23. We can therefore conclude that SNAP23 is an
important t-SNARE in podocytes that mediates insulin-stimulated glucose uptake and is
regulated by binding to septin 7 or pp-RLC.
     It is possible that NMHC-IIA and septin 7 also regulate GSV trafficking via modulating
actin dynamics, as both proteins bind either directly or indirectly to actin. In podocytes,
glucose uptake depends on an intact actin cytoskeleton (Coward et al., 2005) and defective
reorganization  of  actin  filaments  has  been  shown  to  impair  GSV  fusion  with  the  plasma
membrane in adipocytes (Lopez et al., 2009) and muscle cells (Tong et al., 2001). Active
NM-IIA is required for F-actin localization at the plasma membrane in adipocytes (Stall et
al., 2014), and depletion of NMHC-IIA in podocytes leads to loss of actin stress fiber
organization (Hays et al., 2014).
     Further studies are required to characterize the exact steps of GSV trafficking that septin 7
and  NM-IIA  regulate.  Binding  to  the  SNARE  proteins  and  modulation  of  the  SNARE
complex formation by septin 7 and NM-IIA indicate their involvement in GSV tethering,
docking or fusion with the plasma membrane. Whether increased glucose uptake by an
increase in active NM-IIA in diabetes is protective or predisposes to DN requires further
analysis.
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6.4 Does increased insulin sensitivity protect podocytes from injury?
     Several studies have shown the contribution of insulin resistance to the development of
DKD. Insulin resistance correlates with microalbuminuria in both diabetic (Yip et al., 1993;
Parvanova et al., 2006) and non-diabetic subjects (Palaniappan et al., 2003). Furthermore,
insulin signaling is essential for kidney function (Welsh et al., 2010), and podocytes can
develop insulin resistance (Tejada et al., 2008). The protective effect of increased insulin
sensitivity on podocytes could be expected based on several clinical and experimental studies
showing that many insulin sensitizers reduce albuminuria (Jauregui et al., 2009). Studies have
also shown that differential regulation of glucose transporter expression may have a
beneficial role in DN. Overexpression of GLUT1 in podocytes was reported to protect from
DN (Zhang et al., 2010), while podocyte-specific depletion of GLUT4 protects from DN
(Guzman et al., 2014). In this thesis work we identified ezrin, septin 7 and NMHC-IIA as a
novel regulators of glucose uptake into podocytes. More data is needed to conclude how
individual glucose transporters and regulators of insulin signaling and glucose transport
machinery affect podocyte function in vivo, and whether they would provide suitable targets
to enhance insulin sensitivity of the podocytes and to prevent the development or progression
of DN.
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7 CONCLUSIONS AND FUTURE PERSPECTIVES
     This thesis work provides new discoveries in podocyte biology, documents the
involvement of new players, ezrin, septin 7 and nonmuscle myosin IIA in the regulation of
glucose uptake into podocytes, and suggests mechanisms on how this regulation occurs.
     Since podocyte structure and function depend on the regulation of the actin cytoskeleton
and actin organization is altered in many glomerular diseases, proteins that regulate dynamic
actin organization may be potential targets in the treatment of glomerular diseases, including
DN. We found that depletion of ezrin induces reorganization of cortical actin in cultured
podocytes under basal conditions, but diminishes the insulin-induced dynamics of cortical
actin. We also found that ezrin-mediated cortical actin remodelling involves cofilin-1. It is
well known that cortical filamentous actin is important for GLUT4 translocation.
Accordingly, we discovered that knockdown of ezrin increases glucose uptake by podocytes.
Further studies are required to clarify the precise role of ezrin in modulating glucose uptake
activity in vivo,  and  its  effects  on  the  function  of  podocytes.  More  investigations  are  also
required to define whether ezrin regulates the dynamics of cofilin-1 in vivo, and whether the
effect is direct or via other proteins. The specific role of cofilin-1 in regulating the trafficking
of glucose transporters and glucose uptake in podocytes both in vitro and in vivo, together
with ezrin and/or other partners also needs further study.
     Defects in glucose transporter machinery may be one reason for cellular insulin resistance.
Therefore, regulators of glucose transporter trafficking may provide suitable targets to
enhance insulin sensitivity of podocytes and to prevent the development and progression of
DN. Here, we present opposite effects for the filamentous small GTPase septin 7 and NMHC-
IIA on glucose uptake into podocytes, and show that septin 7 and phosphorylated myosin
RLC compete  for  binding  to  the  exocytotic  t-SNAREs.  However,  it  is  unknown if  septin  7
and NMHC-IIA affect insulin sensitivity in podocytes in vivo, and whether septin 7 and
NMHC-IIA also regulate the final steps of GSV trafficking via modulating actin dynamics.
     Collectively, altered expression of ezrin and phosphorylated myosin RLC in the glomeruli
of human patients with diabetes suggests their possible association with the development of
DN. Targeting of ezrin, septin 7 and nonmuscle myosin IIA could be a concept for the
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treatment of podocyte insulin resistance, a strategy that may be prove useful in preventing or
alleviating DN.
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